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Abstract 
Atrial fibrillation is an intermittent disease that causes irregular heart rate and eventual 
atrial myocardium exhaustion. The standard silver / silver-chloride (Ag/AgCl) hydrogel 
electrode is sensitive to moisture and becomes more susceptible to motion artifacts that reduce 
electrocardiogram (ECG) signal quality. FLEXcon USA
©
 has developed a moisture-independent 
and less-expensive electrode design that can improve short- and long-term clinical ECG 
measurement. Ten subjects were recruited for two clinical studies. The first quantified the long-
term biocompatibilities and adhesion strengths of the FLEXcon and hydrogel electrodes during 
seven days; the Gen. 2-A adhesive experienced 7.14% adhesion loss, whereas the hydrogel 
experienced 50% adhesion loss. The second study utilized heart rate variability analysis to 
quantify ECG quality during four days. The correlation coefficients between heart rates 
measured by the FLEXcon and hydrogel electrodes while the subjects were at rest and in motion 
were both 0.997. The acquired results demonstrate that the FLEXcon adhesive and the industry 
standard hydrogel produce statistically similar ECG signals in short- and long-term clinical 
applications. 
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Chapter 1: Introduction 
During the past decade, the population and average lifespan in the United States have 
increased. The improved quality of life has resulted from advancements in the medical field and 
improvements in health care. However, health care expenditures have increased proportionally 
with the growing demand for medical treatment of the elderly and injured. In 2009, hospital care 
and physician services together constituted more than 50% of the $2.330 trillion nationally spent 
on health services, whereas 6.3% was allocated for medical instrumentation and in-home 
treatment (American Hospital Association, 2011).  The average cost of a hospital stay was 
$9,700 in 2010 (Pfuntner et al, 2013), and for many, only a small fraction of these expenses were 
covered by medical insurance.  
Various diagnostic medical procedures, such as cardiac monitoring and sleep studies, 
require the patient to stay in the hospital during the day or overnight. The allocations of medical 
professionals and patient care space are sources of inpatient expenses, regardless of the resulting 
diagnosis. However, medical engineering has innovated diagnostic hospital care by producing 
handheld and wearable diagnostic devices that the patient can use without admission to a 
hospital. The ability to easily measure physiological health factors, such as blood glucose 
content, educates the patient to maintain his or her health at home and prevent medical 
emergencies.  
Although several biological factors can be measured with portable medical 
instrumentation, some of these factors, like cardiac health, still require the analysis of a 
physician. The electrocardiogram (ECG) is the measurement of electrical cardiac activity and is 
acquired by the placement of electrodes on the skin. This electrical signal correlates to the 
nervous and muscular actions that occur during a heartbeat. Abnormal heart function is reflected 
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by changes in the neuromuscular function and ECG — some changes such as escalated heart 
rates are easily observable, but other conditions like mitral valve prolapses and long QT 
syndrome require a trained professional’s diagnosis. The development of portable and handheld 
ECG monitoring devices that can acquire, process, and store the electrical signal has allowed 
physicians to monitor the vital signs of post-surgery patients outside of the hospital. However, 
the quality and accuracy of the ECG are reliant on the performance of the primary sensing unit, 
the ECG electrode, and have a significant impact on the physician’s ability to diagnose cardiac 
abnormalities. 
The Silver/Silver Chloride (Ag/AgCl) hydrogel electrode is the modern gold standard of 
ECG sensing. Composed of a high-moisture hydrogel medium that prevents contact between a 
conductive metal disk and the patient’s skin, these sensors utilize an electrolytic, semi-liquid 
medium that facilitate low-impedance electrical signal transfer from the skin surface. Although 
this electrode system increases sensitivity to electrical cardiac signals with moisture, the gel-like 
layer dries out over time, increasing skin-to-electrode friction and causing significant ECG 
measurement distortions.  
To improve long-term sensor performance, FLEXcon USA
©
 has produced an electrode 
that does not require quickly-drying gels to measure the ECG from the skin surface. This 
electrode design uses a patented Pressure Sensitive Adhesive (PSA) doped with conductive 
compounds to promote high surface area skin-to-electrode adhesion. These electrodes require 
electrophoretic activation prior to clinical use, due to biocompatibility regulations established by 
the Association for the Advancement of Medical Instrumentation (AAMI), to ensure that the 
internal sensor impedance remains less than 2 kΩ. Last year’s Major Qualifying Project (MQP) 
designed a method by which to evaluate the compliance of the FLEXcon electrode with AAMI 
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standards and the electrical short-term performance versus that of the standard Ag/AgCl 
electrode. 
This year, the current MQP group designed and conducted a method of clinically 
comparing long-term FLEXcon and Ag/AgCl electrode performances. This procedure addressed 
the numerous obstacles of physical and electrical interactions between the electrode and the skin, 
such as skin-to-electrode adhesion, repositionability, skin irritation, and ECG signal quality. The 
collaboration with FLEXcon to develop a biocompatible, strongly adhesive, and signal-receptive 
ECG electrode design will provide a means of ensuring high-quality, long-term, and in-home 
vital sign monitoring of post-surgery cardiac patients. 
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Chapter 2: Literature review 
2.1 Bio-potential Electrodes          
Bio-potential electrodes have an important role in medical instrumentation for the 
measurement of physiological signals. Electrodes are made with metals or inert materials, which 
are not toxic to biological tissue and are mechanically strong and have good conductivity for 
detecting electrical signals generated by the body. There are different electrodes for different 
applications that are used in clinical settings today. Types of physiological signal measurement 
encompass: Electroencephalography (EEG) for receiving electrical activity of the brain; 
Electroneurogram (ENG) for receiving electrical response from Peripheral muscles; 
Electromyogram (EMG) for receiving electrical contraction of the muscles; Electroretinogram 
(ERG) for receiving the electrical signal of the retina in the eyes; and Electrooculogram (EOG) 
for measuring the position of the eyes.  
 Electrodes are made in different shapes for different applications. Figure 5 shows an 
electrode that is used in the clinical field is made from silver/ silver chloride (Ag/AgCl) 
surrounded by a gel-coated sponge for better conductive electrical signal. The hydrogel electrode 
is the industry standard of noninvasive ECG measurement in clinical settings but relies on 
moisture for signal acquisition. During long-term applications, the loss of moisture reduces ECG 
trace quality, primarily due to friction and air insulation. Monitoring intermittent cardiac 
anomalies requires constant ECG measurement over the span of multiple days.  
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Figure 1: Typical electrode with all components. 
 There are two types of electrodes: Ag/AgCl and dry electrodes. The advantage of the 
Ag/AgCl electrode is the quality of the signal, however they dry out quickly; therefore, they have 
to be replaced frequently and are not suited for long-term monitoring. Ag/AgCl electrodes are 
also expensive.  
 Novel Dry ECG electrodes are made from compositions of carbon and pressure sensitive 
adhesive (PSA).  Figure 6 shows two main types of electrodes, which FLEXcon is developing.  
 
Figure 2: Dry Electrodes Types Provided by FLEXcon. 
 Dry electrodes have the potential of replacing the hydrogel electrodes, however they also 
have some disadvantages. The last year’s MQP team found some minor problems that needed to 
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be overlooked for a solution to the signal distortion on long term monitoring. In other words, 
based on their conclusion, the dry electrodes have a silver plate on top which could shift due to 
the movement of the patient. The use of the dry electrodes in many cases resulted in puncturing 
of the skin, therefore the use of this method does not facilitate long-term monitoring –scar tissue 
grows around the puncture and increase the impedance of the skin. Since there is a tight bond 
between the skin and the dry electrode there will be moisture in the surface and the impedance 
will decrease.  
2.2 Relevance of the ECG to Clinical Settings 
 Clinical settings, such as hospitals, guarantee proper and effective patient care with 
physiological measurements that characterize the patient’s vital signs. During perioperative 
stages of patient treatment, biological sensors translate vital sign-derived properties, like blood 
pressure and cardiac conduction, into displayable and analyzable quantities and signals. From the 
measured signals, trained medical professionals can determine and monitor the patient’s health in 
real-time during invasive and non-invasive procedures. The electrocardiogram (the signal 
generated by the attachment of electrodes to the skin) is utilized in various medical situations to 
serve as a supplemental or primary method of cardiac function characterization.  
 The ECG can provide electrical information about cyclical cardiac motions and 
contractions. This signal can be correlated to results produced by other methods (such as imaging 
and energy expenditure measurements) to characterize heart function in complex environments. 
To clinically evaluate ventricular function in strenuous environments such as exercise, external 
forces exerted by human subjects onto a cycle ergometer can be correlated to cardiac contraction 
that is simultaneously shown by magnetic resonance imaging (MRI) (Gusso et al, 2012). 
Because the images are generated at a specific frequency, the MRI has no significant meaning 
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unless each image is mapped to a time-dependent cyclical heart function. The ECG is used in 
conjunction with these two devices to provide a time-dependent relationship between the degree 
of cardiac contraction and the periodic nature of cardiac conduction and blood transport (Fratz et 
al, 2013). The incorporation of the ECG demonstrates how modern methods that relate heart 
function to physical stresses and activities require accurate and noninvasive means of heart rate 
measurement. 
 Although clinical studies have demonstrated that there is a direct correlation between 
muscular and cardiac activities, some medical conditions can cause sudden cardiac stresses that 
can be reflected by the ECG combined with blood pressure, blood composition measurements. 
The concurrent use of several vital sign monitoring methods is required to quickly treat a patient 
experiencing sudden physiological instability because a variety of environmental factors could 
contribute to a single medical condition; therefore, the rapid discovery of each contributing 
factor directly contributes to the quick and accurate diagnosis and treatment of the patient’s 
complication. Analyzing arterial blood samples can determine the presence of metabolic and 
nutritional maladies that can be treated with specific medications (Baugher and Mattu, 2011). 
Simultaneously observing the ECG of the patient can suggest whether specific aortic, ventricular, 
and myocardial disorders are affecting cardiac function. If these cardiac disorders are caused by 
arterial blood transfer abnormalities or vice versa, the physician can use these two or more 
diagnostic measurements to accurately diagnose the patient. The ECG is important for in-
hospital diagnoses of patient-specific cardiac ailments, but additional physiological 
measurements are necessary to determine the appropriate treatment due to the interconnected 
nature of the digestive, immune, respiratory, circulatory, and reproductive systems. 
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2.3 Clinical Measurement of the ECG 
 When used in conjunction with other diagnostic processes in a clinical setting, the ECG 
can provide valuable information about the patient’s health. To detect the patient’s ECG, 
electrodes are primarily used. These sensors are attached to specific regions of the patient’s skin 
to detect ionic propagation from the heart to the skin surface and translate the ionic movement to 
electronic current through the electrode body. This electrical current is then processed and stored 
in an acquisition device and subsequently displayed on a monitor to show the ECG to the 
physician.  Each step of this clinical ECG signal acquisition process – skin preparation, electrode 
placement, and signal transmission – requires an array of considerations that contribute to a 
reliable and accurate representation of the patient’s cardiac activity. 
2.3.1 Skin Preparation 
 Prior to the utilization of cardiac sensors in a clinical setting, a variety of procedures 
could be performed to cleanse the patient’s skin. The human dermis is supported by blood 
vessels and periodically regenerates layers of cells to replace the death of outer-surface 
epidermal cells (due to a lack of epidermal blood vessels), causing a superficial layer of dead, 
compressed, and shedding cells to rest on the skin. This layer slightly increases the overall 
thickness of the skin, consequently increasing the impedance – resistance to the transmission of 
electrical current – from the underlying musculature and nerves to the surface electrode (Oster, 
Proper Skin Prep). The thickening of the skin layer and high impedance are ultimately 
responsible for offset voltages and decreased signal-to-noise ratios (SNRs) in the ECG signal. 
Therefore, minimization of the dead skin layer is vital for ensuring ECG quality and facilitating 
subsequent clinician analysis. 
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2.3.2 Electrode Placement 
 Following skin preparation, the electrodes need to be placed on the skin to detect the 
propagation of electrical cardiac signals within the body. The locations and number of electrodes 
used to measure the ECG depend on the application. In clinical practices, the main standard 
electrode configurations are 3-lead, 5-lead, and 12-lead measurements. As more electrodes are 
connected to the patient, more ways of depicting cardiac function are available to analyze, 
altogether helping provide a more comprehensive diagnosis (Barill, 2003).  Ideally, the 
electrodes are placed on the chest because of the proximity to the heart. However, electrodes can 
also be attached to the arms and legs, but larger motion artifacts (due to frictional between the 
electrode and skin) will be present in the signal. The variety of reliable configurations allows the 
clinician to decide how detailed the ECG must be to detect specific cardiac irregularities; for 
obvious discrepancies in the waveform that characterize easily discernible diseases, fewer 
electrodes are required to detect that abnormality. 
2.3.3 Signal Transmission 
 Measurement of the ECG can be accomplished in the hospital and at the home. The 
nature in which the ECG must be measured determined what kind of apparatus must be used to 
collect and store the signal. For stationary measurements, large machines can be used to receive, 
store, and digitally process the data with a detailed user interface. However, longer-term 
measurements often involve patients or subjects moving around and require a smaller, 
lightweight signal-storing apparatus. Clinical studies that correlate dietary habits and cardiac 
function utilize mobile ECG systems to collect the cardiac signals while subjects perform 
everyday tasks (Yamakoshi et al, 2013). The development of mobile ECG systems has equipped 
biomedical research with a means of characterizing heart function in dynamic environments. 
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2.4 Clinical Diagnosis of Cardiac Abnormalities 
After the acquisition and filtering of the ECG signal, the physician can observe the signal 
to detect abnormalities. Various cardiac dysfunctions cause characteristic transformations in the 
ECG signal. Irregularities such as atrioventricular block and ventricular arrhythmias cause 
delayed electrical signal transmission from the atrioventricular node to the purkinje fibers that 
control ventricular contractions). This pumping of blood from the atria into the ventricles 
corresponds to the ECG R-wave. Therefore, the delay in blood transfer to the ventricles is 
reflected by a normal P-Q wave complex that is separated from a delayed R-wave by a prolonged 
pause (Yodogawa et al, 2007). Other abnormalities, such as mitral valve prolapse, can affect an 
entire complex of waves in the ECG. In the 3-lead configuration, the slight backflow of blood 
from the ventricle back into the atrium through the slightly open mitral valve causes an inverted 
T-wave and an elevated S-T wave complex in the ECG (Manenti et al, 2013). Changes in the 
ECG waveform can show how any cardiac disease may alter the ECG signal substantially; this 
signal transformation allows the clinician to easily diagnose and treat the patient immediately, 
preventing severe injury or death. 
2.5 Clinical Evaluation of Electrode Performance 
 Because the electrode is the primary sensor used to measure the ECG, the physical 
properties of the sensor determine how well the signal is recorded. The ability of an electrode to 
adhere strongly to the skin surface determines the quality of the signal. When the adhesion 
between the electrode and the skin is stronger, the isolation of the skin-to-electrode interface is 
increased, and environmental interference is reduced (Cömert, Honkala, and Hyttinen, 2013). 
There are various ways to quantify and describe the adhesion and biocompatibility of these skin-
adhesive biological sensors.  
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 Electrode-to-skin adhesion can be quantified by various quantities. Devices that measure 
force, pressure, torque, and shear can be used to accurately simulate peeling motions with high 
precision (Murakami et al, 2012). A more qualitative approach is the use of clinical feedback. 
After peeling the electrode from the skin, subject can complete a survey (0 – 10) that evaluates 
how much pain the person felt. Higher perceived pain corresponds to increased adhesion (Austin 
and Patel, Considerations). In clinical studies, the utilization of mechanized instruments 
increases measurement capabilities at the expense of financial cost, whereas simple qualitative 
tests are easier to perform with greatly diminished accuracy and resolution. Therefore, a balance 
of mechanical and subject-feedback tools should be utilized together to provide a detailed 
description of surface-to-surface adhesion. 
 Analogous adhesion measurements, the evaluation of skin irritation can be conducted 
qualitatively or quantitatively. The most widely used qualitative assessment is the use of a survey 
that asks whether the patient has experienced epidermal allergies such as itchiness, dryness, or 
scaling (Boyce, Kelliher, and Vallande, 2000). Alternatively, the measurement of skin 
capacitance can be used to characterize skin swelling and water content, both of which are 
symptoms of oedema. When the skin is exposed to an irritant, the fluidic retention of the 
epidermis increases. Because the degree of swelling is proportional to the degree of water 
retention, ultrasonic devices can be used to determine the thickness of the skin and correlate that 
thickness to the degree of irritation (Miettinen et al, 2006). In clinical studies, a combination of 
qualitative surveys that document sensations and devices that measure skin water retention can 
fully characterize human skin reactions to applied adhesives.  
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2.6 Digital Signal Processing 
 The ECG sensor output is an electrical analog signal that is transmitted in real-time. 
However, this signal is generally not ideal or perfect, due to background noise, motion artifacts, 
and offset voltages. Modern apparatuses utilize analog components to receive the signal that is 
transmitted from the electrodes through wire leads. Because printed circuit boards and 
microprocessors are becoming more efficient and less expensive, digital filtering and signal 
correction is utilized by analog-to-digital conversion techniques. The use of digital filtering is 
more efficient than analog filtering because analog circuits are heavily impacted by temperature 
changes, whereas digital components can sample the real-time signal, store the data (which 
cannot be corrupted by ambient temperatures), and perform rapid computations. 
 Embedded signal processing has incorporated much more software-based operations to 
minimize the need for additional analog parts. The hardware is designed to convert and store the 
data, and the software allows the engineer or physician to control how the data is processed. In 
the clinical setting, a variety of digital filtration algorithms in these user interfaces help the 
physician perform quick and reliable analyses of ECG waveform data. To detect arrhythmia, the 
signal is filtered to remove noise, artifacts, and voltage drift to improve signal detail. Then, 
changes in the QRS wave complex of the ECG (the periodic global signal maximum) are 
detected with a threshold algorithm (Kim et al, 2011). The QRS complexes of these filtered 
signals are then expressed in the frequency domain (as a mixture of sinusoidal waveforms). The 
signal magnitude profile has a lower frequency (slower rate of cardiac depolarization) than that 
of a healthy ECG signal if arrhythmia is affecting the patient. The ability to characterize the rate 
at which cardiac function is changing is an important result of fast and compact embedded signal 
processing with minimal instrument variability.  
Long Term Clinical Evaluation of Novel ECG Electrodes   
 18 
Digital processing reduces component costs, minimizes device weight, and facilitates 
high-level analyses and computations. The incorporation of embedded algorithms in hardware 
for specific disease detection mechanisms minimizes the time required for computations; the 
rapid passage of information through these software circuits serves as a signal filtration method 
with a negligible time-lag that is comparable to real-time analog signal processing. In the 
emergency room, where patient health can quickly decline during invasive surgery, the high 
precision and minimal response time of digital ECG-processing systems help surgeons and 
physicians keep the patient alive and stable. 
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Chapter 3: Project Strategy 
3.1 Initial Client Statement           
The initial client statement was proposed by FLEXcon to the MQP team on September 11, 2013: 
 “Starting with prior ECG MQP, update Test Protocol Methodology based on Association for the 
Advancement of Medical Instrumentation (AAMI) for evaluating long term use of electrodes. 
Perform 2 design of experiment (DOE) processes to determine synergistic effect of electrode 
performance which including signal quality and susceptibility to interference. Report results 
using this technique. Product recommendations (compared to hydrogel ECG control) based on 
analysis (constrained within limits of the given design). Recommendations on what to improve 
based on their understanding of the application requirements.” 
3.2 List of Objectives 
The team carefully read the client statement and consulted with its advisor, Professor Chon. The 
team was able to identify six desirable characteristics of the design method. The first objective 
the team found was long-term ECG measurement. This objective is the main goal of the 
company. By talking to the sponsors and advisor, we defined a long term measurement time 
frame as 7 or fewer days, which is within the regulations of Associations for Advancement of 
Medical Instruments (AAMI). The second objective was safety because the team needs to 
consider the health of each human subject in order to avoid inhumane means of data acquisition. 
Safety for human subject will include limiting skin irritations, accounting for allergies, and 
preventing electrical shock from the testing instruments. The third objective was the comparison 
of novel ECG electrodes with hydrogel electrodes. The comparison of both electrodes will 
require proper skin preparation and the performance of electrodes in long and short term 
measurements. Also, the electrodes will be compared based on storage in extreme conditions 
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prior to use. The fourth objective is signal processing. Means of developing mathematical 
algorithms are important for facilitated calculation of heart rate and signal noise. The ability of 
the two electrode types to measure these parameters will facilitate the comparison of electrode 
performance. The fifth objective is comfort of the ECG electrodes on the human subjects. The 
well-being of the subject is important because this design method must not interfere with his or 
her daily activities and ensure that the subject behaves naturally during the experiment. The final 
objective is minimum instrumentation and subject cost because the equipment has to be reliable, 
the subject have to be given proper incentives to follow the experimental protocol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Long Term Clinical Evaluation of Novel ECG Electrodes   
 21 
Table 1: Pairwise comparison of project objectives. 
   Minimum 
instrumentatio
n and subject 
cost 
Comfor
t 
 
Safet
y 
  Long-term 
measureme
nt 
Compariso
n of novel 
and 
hydrogel 
electrodes 
Signal 
Processin
g 
Tota
l 
 Minimum 
instrumentatio
n and subject 
cost 
XXX  0.5  0  0  0  0  0.5 
Comfort  0.5 XXX  0  0  0  0.5  1 
 Safety  1  1 XXX  0.5  0.5  1  4 
  Long-term 
ECG 
measurement 
 1  1  0.5 XXX  0.5  1  4 
Comparison 
of novel and 
hydrogel 
electrodes 
 1  1  0.5  0.5 XXX  0  3 
Signal 
Processing  
 1  0.5  0  0  1 XXX  2.5 
 
 
       
 
3.3 List of Constraints 
 Because the subject must act naturally and perform his or her personal daily routines, the 
instrumentation must weigh less than 1 pound. Also, the length of these clinical trials cannot last 
longer than seven days because AAMI regulations prohibit overly strenuous experimental 
conditions. This seven day period mimics the longer time period of inpatient ECG monitoring in 
hospital facilities. The number of recruited subjects and the amount of compensation are 
constraints because we want to minimize the expenses that are used by this method but require a 
sufficient amount of data to show the performance of the electrodes. For this procedure, we have 
a limited number of ECG data storage devices to distribute to subjects, which limits the number 
of subjects that can be monitored at a given time.   
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3.4 Revised Client Statement 
After the definition and clarification of our objectives and constraints, we sought to 
define how the Design of Experiments should be made to accomplish the objectives and stay 
within the limitations of the constraints. Therefore, our revised client statement encompassed the 
following tasks: 
• Design a clinical study that abides by AAMI regulations to measure the SRM-to-skin 
adhesion, repositionability, skin irritation, and moisture resistance of three novel ECG 
electrode designs (and a standard hydrogel electrode) over the course of 7 days.  
• Based on the results of the first clinical study, design a second clinical study that will 
compare the electrocardiogram signals acquired from a single novel electrode design 
and a standard hydrogel electrode over a period of 7 days. 
• Develop a method of digital signal processing that will reduce background noise without 
causing signal distortion. This processing system must be applied to the ECGs acquired 
by the novel and standard electrodes. 
• Recommend what to improve based on the group’s understanding of the application 
requirements  
 3.5 Project Approach 
 Based on the revision of the client statement, this project comprises three main goals: 
evaluate the short-term and long-term physical properties of novel and Ag/AgCl electrodes; 
measure the short-term and long-term electrical signals transmitted by novel and Ag/AgCl 
electrodes; and process the acquired signals to compare the overall performance of both 
electrode types. To accomplish these three goals, the group developed a three-stage project 
design each stage or phase will accomplish an individual goal and determine how the next stage 
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will be conducted. Phases I and II are primarily clinical studies that must be designed to produce 
data, whereas Phase III is a digital system that must be designed to process the collected data. 
 The first phase of the project is the evaluation of physical properties (skin adhesion, 
repositionability, and skin irritation) that characterize the performance of FLEXcon’s novel 
electrodes and the traditional Ag/AgCl electrodes. Prior to experimentation, we need to help 
FLEXcon design the composition of electrode substrates (the material that composes the backing 
of the tab electrode) to determine 3 testable, flexible electrode designs. Within this phase, this 
study must encompass the design of a simple, user-friendly, and safe method of measuring the 
peeling force required to remove electrodes from the skin. This test is meant to evaluate the 
repositionability of each electrode type and replicate clinical, in-hospital scenarios in which 
electrodes have to be repositioned due to human error. In this phase, a second experiment has to 
be conducted simultaneously to evaluate skin irritation every 24 hours. Although electrodes are 
meant to be disposable, we need to determine how signal integrity changes over longer periods 
of time and test long-term performance during in-home diagnostic medical procedures.  
The second phase uses the results from Phase I to select a single experimental electrode design to 
test, versus the traditional hydrogel electrode. Two experiments will be run in parallel to measure 
(1) the long-term ECG and (2) the ECG signal quality versus short-term repositioning. In this 
phase, we need to design methods of measuring the ECG of the subjects during the day and store 
the data without impeding everyday activities.       
 Lastly, Phase III will be conducted to design a digital filtering system that will compare 
the ECG signals recorded from the two electrode types. Measuring heart rate, motion artifacts, 
and other quantities will complete this comparison.  
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3.5.1 Financial Project Management 
 The group and its advisor discussed feasible remuneration quantities with which to 
compensate subjects. To decide an exact quantity, we had to determine which quantity would 
give enough incentive to follow a 7-day, day-to-day procedure, come to the lab for an initial 1-
hour session, and return every 24 hours for diagnostic and data-collecting 20- minute sessions. 
We concluded that $200 for the participation in this 7-day study would be sufficient to guarantee 
compliance. Therefore, if we need a total of 20 subjects for Phases I and II a total of $4,000 will 
be needed for adequate remuneration. Also, to make sure that our protocols conform to AAMI 
regulations, we need to purchase up-to-date documentation ($190). The Biomedical Engineering 
Lab and our advisor will provide Holter monitors and other ECG monitoring software.  
Lastly, we need to determine how many electrodes will be used throughout the study. Below, we 
have constructed a table that shows how many electrodes will be required to conduct all of our 
clinical studies. 
 
Table 2: Calculation of projected electrode count required to complete both clinical studies. 
 
Based on these calculations, we cannot immediately determine how much these custom 
experimental electrodes will cost. However, we know that we will require a total 400 
experimental electrodes (360 + extra). Based on online market prices, we estimated that 100 
Ag/AgCl electrodes (60 + extra) will be required, yielding a total expense of approximately $26. 
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Clinical Experimentation Design Evaluation Matrix (Design of Phases I and II): A comparison 
of macro-scale clinical study designs that emphasize the overall recruitment and equipment 
feasibility. 
Table 3: Numerical Evaluation Design Matrix utilized to determine feasibility of subject recruitment. 
Objectives (O)and 
Constraints ( C ) 
200 subjects, 50 
subjects for each of 
4 experiments 
20 subjects, 10 
per phase (I 
and II), Use of 
Bio-Pak ECG 
system 
40-subject 
recruitment, 10 
subjects for each 
of 4 
experiments, 
Mobile Holter 
ECG Monitors 
20 Subjects, 10 
per phase (I 
and II), Mobile 
Holter ECG 
monitors 
Lightweight 
instrumentation 
 ( c ) 
 X   
Complies with 
AAMI standards 
 ( c ) 
    
Minimizes # of 
subjects ( c ) 
    
Minimizes number 
of subjects ( c ) 
X    
     
safe (O)   100 100 
Long-term ECG 
measurement (O) 
  100 100 
Comparison of 
Novel and AgCl 
(O) 
  100 100 
Signal Processing 
(O) 
  70 90 
Comfort (O)   90 80 
Minimize 
instrumentation 
cost (O) 
  50 80 
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Table 4: Gant Chart of planned project progress throughout the academic year. 
 
Figure 3: Work breakdown structure for planning of two clinical studies and subsequent signal processing. 
 
 
 
 
 
Gant Chart Term A Term B Term C Term D
Weeks 1 3 5 7 Week 8: off 1 3 5 7 16-Dec 16-Jan 1 3 5 7 Week 8: off 1 3 5 7
•Background
•Design Phases 1 and 2
•Complete and submit IRB
•Subject recruitment for Phase 1
•Conduct Phase 1 Experiments
•Design Phase 3
•Subject recruitment for Phase 2
•Conduct Phase 2 Experiments
•Process Phase 2 results with Phase 3 
•Final report and presentations
Novel ECG 
Electrodes 
IRB and 
Protocol 
Phase #1 
Mechanical 
Property 
Pre-
Experimentati
on 
Substrate 
Experiment #1 
Skin adhesion 
Repositionabil
ity 
Quantitative 
force 
Experiment #2 
Skin irritation 
long term 
Qualitative 
outputs 
Inflammation 
Phase #2 
Electrical 
Performance 
Experiment #1 
Signal Quality 
Repositioning 
Electrode 
configuration 
Experiment #2 
Signal quality 
long term  
Electrodes 
configuration 
Phase #3 
Signal 
Proccesing  
Matlab coding  
Amplification 
Filtration 
Peak 
detection 
ECG shape 
PQRST 
Documentatio
n 
Final 
Presentation 
Final Report 
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Table 5: Function and Means Table utilized to suggest feasible methods of completing the main objectives of all three phases. 
Functions Means 
Measure 
skin 
irritation 
Capacitive 
skin 
moisture 
retention  
Subject 
feedback 
survey 
European 
skin prick 
test 
OET 
irritation 
potential 
test 
Draize 
irritation 
potential 
test 
    
Measure 
skin 
adhesion 
Force 
Transducer 
Pressure 
Transducer 
Shear 
transducer 
Torque 
Transducer 
Gravity     
Store 
ECG 
signals 
Desktop 
computer 
hard drive 
Mobile Laptop External 
hard drive 
Holter 
monitor 
Bio-Pak 
system 
    
Analyze / 
process 
ECG 
signals 
Analog 
components 
Microprocessor 
(C 
programming 
language) 
MATLAB Band-pass 
filter 
Notch 
filter 
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Chapter 4: Project Design Process 
4.1 Introduction 
Based on the revision of the client’s statement, the group developed a list of design 
requirements that could guide the formulation of a clinical study that will assess the physical 
properties of experimental electrode adhesives. Before designing the clinical study, the group 
was responsible for selecting the electrode body material to which each adhesive could be 
attached. The design of the electrode body material will be used to maintain the integrity of the 
adhesive by providing structural support and sufficient flexibility. By minimizing environmental 
interference, the electrode body will allow the clinical study to effectively compare the FLEXcon 
adhesives’ interactions with skin to those of a standard hydrogel. 
4.2 Needs Analysis 
Next, a clinical study must be designed to meet specific requirements to produce reliable 
results. The primary functional needs of the clinical study are safety and long-term evaluation 
capabilities. These two requirements were ranked equally because jeopardizing the health of the 
subjects would eliminate the integrity of any long-term data, and the ability to collect long-term 
data is important for interpretation of the client’s electrode performance.  
The two major goals of this clinical study are: the evaluation of physical skin irritation 
every 24 hours, for seven days; and the measurement of adhesion strength between FLEXcon’s 
electrodes and human skin, to a precision of 0.1 N. Also, this study must allow us to measure the 
subject’s ECG continuously over 4 days.  
The major limitations of the study are electrode size and instrumentation weight. Because 
this study is meant to replicate the conditions used in long-term clinical monitoring, the shape 
and size of the tested electrodes must be comparable to those produced in the medical industry. 
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Also, minimizing the weight of heart rate monitoring instrumentation is important for improving 
subjects’ comfort. The group determined that collection of two sets of ECG data should require 
no more than 2 pounds of equipment. 
4.3 Procedure and System Designs 
4.3.1 Electrode Body Material Design  
The design of the electrode body was a major design component with a focus on stress-
dependent moduli, such as maximizing resistance to shear stresses; maximizing tensile 
resistance; and maximizing flexibility. To prevent erosion of the material, the electrode body 
must be chemically resistant to salt and fresh water, weak acids, and weak alkali that are secreted 
on the surface of the skin. 
CES EduPack, a database of modern materials, was utilized to generate a list of possible 
electrode body materials and compare their physical properties.  
As shown in Table 6, eleven different materials were selected for a comparison of 
chemical stabilities. The skin secrets sweat that contains extremely small concentrations of 
alkaline and acidic compounds; a majority of its composition is sodium and chloride dissolved in 
water (Fukumoto et al, 1988). Therefore, the resistances of each material to weak acids and 
alkali, fresh water, and salt water were analyzed and compared. This database used a scale in 
which a value of zero signified little to no durability in response to exposure to a specific type of 
substance, and a value of five represented high resistance to the specified compound.  
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Table 6: CES EduPack descriptions of material durability ratings during exposure to compounds of varying acidity. 
 
 A summation of the resistance values was calculated for each of these eleven materials, 
and the five materials with the greatest scores were selected for a secondary comparison. This 
secondary comparison was utilized to select a material that could provide sufficient mechanical 
structure to an attached adhesive in reaction to force loading. As shown in Table 7, the Young’s 
Modulus characterized resistance to tension and stretching; the flexural modulus described 
material response to bending, and the shear modulus explains material reactions to shear forces. 
These moduli, in addition to the threshold strengths of the stress-strain curves, were considered 
in the selection of electrode substrate materials. 
Table 7: Descriptions of material resistances to shear, tensile, compressive, and flexural stresses. 
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4.3.2 Skin Irritation Experiment Design  
In Phase I of the clinical study, five different types of ECG electrodes were tested on ten 
human subjects. FLEXcon provided four experimental adhesive compositions: Generation 1 
(Gen. 1), Generation 2 (Gen. 2), Generation 2-A (Gen. 2-A), and Generation 3 (Gen. 3). The fifth 
adhesive was the Ag/AgCl hydrogel that is utilized as an industry standard in hospital settings 
today. The team’s objectives were the testing of all five types during a seven-day trial, the 
collection of data from each type, and the analysis of the collected data to determine which 
FLEXcon adhesive was as biocompatible and mechanically stable as the standard hydrogel. The 
best-performing FLEXcon adhesive was subsequently tested in a second clinical study (Phase II) 
that measured signal quality. 
  By monitoring each subject each day for a period of one week, we were able to 
distinguish the severity of skin irritation in each subject, and determining the best performing 
ECG electrodes during long-term monitoring. The long-term biocompatibility experiment was 
designed to recruit a diverse subject population with a variety of skin types. The skin type and 
ethnicity of each subject is listed in Table 8. The different types of skin that were chosen would 
provide a comprehensive understanding of the effect of irritation, but also simulate a real life 
clinical setting.  
Seven electrodes of each type were placed in rows, as shown in Figure 9, on each 
subject’s forearms. Each day, one electrode of each adhesive type was removed, and the skin was 
carefully examined for signs of irritation, such as redness or discoloration. After the daily 
procedure was complete, the individual was given two different questionnaires, which were 
related to discomfort, irritation and itchiness experienced in the past 24 hours. This survey was 
then processed in excel for later analysis of each type of electrode.  
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Figure 4: Electrocardiogram electrode placement inside the forearms. 
 
Table 8: Demographic information (Skin moisture content and ethnicity) of each subject who volunteered to participate in the 
Phase I studies. 
 
4.3.3 Removal Force Experiment Design 
The first clinical study procedure has to apply tension to the center and edges of 
electrodes and provide precise force measurements. 
For force measurement and application, there is no limitation of instrumentation weight 
or dimensions. However, the utilized device must allow us to control peeling velocities and 
angles as well as provide precise force measurements in real time. A study has demonstrated that 
peeling forces required to remove clinical adhesives from patients’ skin have magnitudes of less 
Subject #1 Subject #2 Subject #3 Subject #4 Subject #5 Subject #6 Subject #7 Subject #8 Subject #9 Subject #10
Ethnicity Hispanic East EU East EU East EU Hispanic West EU S. Asian Afr. American West EU / Hispanic E. Asian 
Skin Type Moderate Dry Dry Moderate Moderate Moderate Dry Oily Moderate Oily
Subjects
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than 5 Newton’s (N) (Murahata, Taylor, Damia, Houser, and Grove ). Therefore, the group 
decided that a precision of 0.1 N was needed to sufficiently characterize the peeling force profile. 
The evaluation of adhesive resistance to lead wire pulling forces requires capabilities of 
measuring larger tensile strengths. Another study demonstrated that the force acting on the 
electrode body is experienced by the attached wire, causing lead retention as large as 50 N 
(Coggins, 2010). Therefore, the clinical study would have to include methods of measuring a 
wide range of tensile forces. 
Table 9: Function means chart describing alternative methods of applying tensile force and connecting a force transducer to the 
electrode body. 
Functions Means 
Exert Force Spring Manual Hydraulic 
Machinery 
Weights / 
gravity 
     
Connect 
Transducer 
to Electrode 
String Clamp Wire Adhesive      
          
After selecting tensile force as a descriptive measure of adhesive strength, the group 
discussed multiple modes of tensile force application as well as a variety of connections between 
the electrode body and the transducer.  
Each method of force application has its own benefits and disadvantages. A spring 
system would allow the group to precisely measure the displacement of the spring and quickly 
calculate the potential energy (and force magnitude) required to remove the electrode from the 
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skin; however, the spring could break if it is too weak, or the release of the spring recoil 
immediately after electrode removal can injure the subject.  
Hydraulic or high-powered machinery would provide a precise and steady control of 
peeling rate, but the components are often expensive, heavy, and require extensive training prior 
to use. The short project timeline would cause restrictions on resource and assistance availability.  
Weight suspension can guarantee adjustable peel angle and facilitated force measurement 
based on mass; however, the weights themselves have very low precisions in mass measurement. 
Because the tested adhesives are experimental, their strengths have not been tested. Therefore, 
measuring the necessary force to remove the electrode from a substrate by incrementing the 
applied mass at larger intervals would prevent the group from determining whether the weight is 
exactly or above the adhesive strength threshold. 
 A manual pulling motion can serve as an alternative method of tensile force application. 
Manually applying tension will allow the group to control peeling angle, rate, and force 
magnitude easily; however, neural control of muscular contraction causes fluctuations in 
contractile force steadiness. Motor neurons stimulate two types of skeletal muscle, slow-
twitching (Type I) and fast-twitching (Type II), at rates of 10-20 Hz and 30-60 Hz, respectively. 
The combination of these stimulations allows the muscle to quickly provide large forces (using 
the Type II fibers, which contract and relax quickly) and sustaining that force magnitude (with 
the Type I fibers, which contract and relax slowly) in tetanus contraction (Webster 144-146). The 
mechanical force profile reflects the fluctuation of force exertion with peaks upon fiber 
contraction (propagation of electrical signals into the neuromuscular junctions) and valleys upon 
relaxation (the temporal gaps between neural stimulation). 
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 Next, the group brainstormed a list of possible methods of attaching the force application 
source to the electrode body. The advantages and drawbacks of string, clamps, wires, and glues 
were analyzed.  
 The main advantages of string and wire are their flexibilities. In the design of the clinical 
study, peel angle must be controlled or adjusted to simulate the overall force vector of a clinical, 
manual peeling motion. However, at higher tensile stresses, the string can stretch or break. The 
failure of the string during an experiment can waste materials and hamper experimental 
processes if the removal force is greater than the string’s yield stress. Securing the string or wire 
to the electrode would require tying it around the metal electrode tab for central pulling motions 
and threading through a hole in the electrode edge for peeling motions. Although the string and 
wire would be easy to remove, altering the electrode body would increase the likelihood of 
tearing the electrode tab because the loop would apply constrictive forces along the tensile 
force’s directional vector.  
Adhesives could be used to bond the transducer to the electrode body. Therefore, the 
mechanical adhesion between the two subtracted would be stronger. Although the mechanical 
stability of the system would be increased, the electrode cannot be interchanged easily with 
another. The ability to disengage the transducer from the electrode in a facilitated fashion is 
important for transducer calibration between force measurement trials. 
A clamping mechanism would provide a different approach to attaching the transducer to 
the electrode body with a grasping action. This method replicates the grip that human hands use 
to peel an electrode by its tab, pressing on both sides of the tab to cause compression normal to 
both the direction of the pull and the plane of the electrode tab.  
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4.3.4 Signal Processing Algorithm Design 
The signal processing of the raw data was done by using the programing language 
MATLAB. The code was designed to process the ECG signals. Before starting to write the code 
for signal processing, it was needed to know that the Holter monitor save data in discrete time 
and the sampling frequency is 180 samples per second. Based on the sampling frequency, the 
code was design to detect all peaks of ECG signal. The code includes loading the data, sampling 
frequency and time vector. Next, a series of filters (band-pass, derivative, and moving average) 
were utilized to remove noise from the ECG signal and locate R waves. The gains of these filters 
(Equations 1 – 7) were derived from the literature, as provided by (Pan and Tompkins, 1985). 
The last part of the peak detection was the selection of the threshold that was applied to the 
output of the moving average filter. This threshold established index-based peak-searching 
domains that defined the plausible locations (in time) of QRS complexes. 
 First, the raw data of ECG saved from all the subject are loaded to the program by using 
the code below. The code below shows an example for loading data saved form Holter monitor 
and BIOPAC system. 
%% Read data 
data = load ('S8_R1.txt');    % Load data collected with Biopac system 
fc = data(:,2);     %FLEXcon electrode data in second column, in Volts 
ag = data(:,1);     %Ag/AgCl electrode data in first column, in Volts 
data1 = load ('3-fc-d3-e.csv'); % Load data collected with Holter  
fc = data1(:,3);    %FLEXcon electrode data uses channel 3, in Volts 
data2 = load ('3-ag-d2-e.csv'); % Load data collected with Holter  
ag = data2(:,3);     %Ag/AgCl electrode data uses channel 3, in Volts 
fc= fc(1:24000);     %Specified range of data for FLEXcon 
ag= ag(1:24000);     %Specified range of data for Ag/AgCl 
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% All FLEXcon variables began with “fc” and Ag/AgCl variables with “ag” 
 
 The load function on Matlab imports all data into a matrix MxN, where N is the number 
of rows and M is the number of columns. The text file have a matrix 2xN which first column is 
Ag/AgCl data and second column is FLEXcon data. The csv file has 3 columns which are three 
channels of Holter monitor.   
Second, sampling frequency which was specified by the sampling frequency of the 
instrumentation used during ECG measurement (200 or 180 Hz). Also this code finds the 
duration of the entire data and returns the time in seconds and plot the raw data.  
%% The Number of Samples per 1 second and  
                 %the duration of the signal with time vector 
%Fs=200;  % Biopac system sampling frequency 
Fs=180;   % Holter monitor sampling frequency 
dt=1/Fs;  % time step between each sample 
duration=length(fc)*dt; % the duration of data in seconds (2 minutes) 
t=0:dt:duration-dt; % The vector of time 
t=t';   % it changes the columns to rows 
 
 Next, this part of the code removes all DC noise which caused by movement of the 
subjects. After, the code plots both ECG signals on same plot with a legend as it is shown on 
figure below.  
%% Remove the DC noise of the signal 
fc=fc-mean(fc); %FLEXcon signal  
ag=ag-mean(ag); %Ag/AgCl signal 
%% Plots the Raw data after removing DC noise. 
figure(1)  
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plot(t,fc); % Plots FLEXcon signal 
grid on; hold on; 
plot(t,ag, 'r-.');  % Plots Ag/AgCl signal 
xlabel('Time [s]'); 
ylabel('Voltage [V]'); 
title('Raw ECG Waveform'); 
legend('FLEXcon','AgCl'); 
 
Figure 5: FLEXcon signal and Ag/AgCl signal after the removal of DC noise 
 Fourth, this part of the code is very important part of the signal processing. This part is 
band-pass filter which was constructed by using low-pass filter and high-pass filter. The signal 
goes first in low pas filter and then in high-pass filter. The cut off frequencies for band-pass filter 
are 5 Hz for low frequency and 11Hz for high frequency. This band-pass filter removes the 
power line interference of 60 Hz.  
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The low pass filter algorithm was design from the transfer function of the second – order 
as it is shown in equation 1. The difference equation of this equation 1 is shown in equation 2 
which is low pass filter that pass low frequencies from 0 to 11Hz.  
Equation 1:    ( )   
(     )  
(     )  
 
Equation 2: Y(nT) = 2y(nT-T)-y(nT-2T)+x(nT)-2x(nT-6T)+x(nT-12T) 
 The high pass filter algorithm was driven from first order transfer function which is 
shown in equation 3. The difference equation was founded from the transfer function of equation 
3 is shown in equation 4. This difference equation is high pass filter which passes all frequencies 
above 5 Hz. The band-pass filter was crated from equation 2 and 4 with cut off frequencies 5 Hz 
and 11Hz.  
Equation 3:  ( )   
(              )
(     )
 
Equation 4: Y(nT) = 32x(nT-16T)-[y(nT-T)+x(nT)-x(nT-32T)]    
 
 
%% Low-pass filter 
bl=[1 0 0 0 0 0 -2 0 0 0 0 0 1]; % Coefficients b of the difference 
%equation of lowpass filter 
al=[1 -2 1]; % Coefficients a of the difference equation of low-pass 
%filter 
fc_lp=filter(bl,al,fc); %FLEXcon low-pass filter 
ag_lp=filter(bl,al,ag); %Ag/AgCl low-pass filter 
 
%% High-pass filter  
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bh=[-1 zeros(1,15) 32 zeros(1,15) 1]; % Coefficients b of the 
%difference equation of high-pass filter 
ah=[1 1]; % Coefficients a of the difference equation of high-pass 
%filter 
fc_hp=filter(bh,ah,fc_lp); %FLEXcon high-pass filter 
ag_hp=filter(bh,ah,ag_lp); %Ag/AgCl high-pass filter 
figure (2) 
plot(t,fc_hp); %FLEXcon signal after band-pass filter  
grid on; hold on; 
plot(t,ag_hp, 'r-.'); %Ag/AgCl signal after band-pass filter  
xlabel('Time [s]'); 
ylabel('Voltage [V]'); 
title(' Bandpass Filter of ECG Waveform'); 
legend('FLEXcon','AgCl'); 
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 Fifth, after filtering the signal, it is needed to take the derivative of the signal and then 
square it. This provides only positive values and accentuates larger values. This manipulation 
made it easy to detect peaks and their time locations. This was the best way to get higher 
accuracy of peak detection. The transfer function used for the derivative used 5 points which had 
transfer function as is shown in equation 5 and the difference equation 6 was derived from 
equation 5.  
Equation 5:  ( )   (    )(                ) 
Equation 6:  (  )  (
 
 
) [  (     )    (    )    (    )   (     )] 
%% Derivative filtering, squaring 
bd=(1/8)*[2 1 0 -1 -2]; % Coefficients b of the difference equation of 
derivative function 
ad=[1]; % Coefficients a of the difference equation of derivative 
function 
fc_der=filter(bd,ad, fc_hp); %FLEXcon derivative filter 
ag_der=filter(bd,ad, ag_hp); %Ag/AgCl Derivative filter 
fc_sq=(fc_der).^2; %FLEXcon, signal squared of derivative 
ag_sq=(ag_der).^2; %Ag/AgCl, signal squared of derivative 
 
 After utilization of the derivative filter, moving average filter was used for both signals. 
This code helped to set up the threshold which all the R-peaks are above it. The threshold was set 
below of all the R-peaks which made it easy to find them all without losing any peak. The 
moving average difference equation is shown in equation 7. Threshold was set after the moving 
average filter and it was set by the algorithm provided below. 
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Equation 7:  (  )  (
 
 
) [ (   (   ) )   (   (   ) ) )     (  )]   (7) 
%% Moving average filter 
N=30; % Moving average filter length  
bm=(1/N)*[ones(1,N)]; 
am=[1]; 
fc_m=filter(bm,am,fc_sq); %FLEXcon Moving Average filter 
ag_m=filter(bm,am,ag_sq); %Ag/AgCl Moving Average filter 
%% Thresholds set by the mean of MA signal  
thr_fc= mean(fc_m); %Threshold for FLEXcon  
thr_ag= mean(ag_m); %Threshold for Ag/AgCl  
fc_p=zeros(size(fc_m));%Set all values below threshold to zero, FLEXcon 
ag_p=zeros(size(ag_m));%Set all values below threshold to zero, Ag/AgCl  
fc_p(find(fc_m>=thr_fc))=1; %All values above threshold are 1 FLEXcon 
ag_p(find(ag_m>=thr_ag))=1; %All values above threshold are 1 Ag/AgCl 
 
 Finally, the code below finds all the peak located above the threshold with specific time 
location and make a mark on R wave of the ECG signal. After all the peaks are found, they were 
counted and then computed the heart rate which was given in beats per minute’s BPM. All the 
peaks for FLEXcon are marked with circle “o” and Ag/AgCl peaks are marked with star “*”.   
%% searches for peaks between rising edges and falling edges 
a1=diff(fc_p); %Derivative of square signal, FLEXcon 
a2=diff(ag_p); %Derivative of square signal, Ag/AgCl 
upindex_fc=find(a1==1); %Rising edges for FLEXcon 
upindex_ag=find(a2==1); %Rising edges for Ag/AgCl 
downindex1=find(a1==-1);%Falling edges for FLEXcon 
downindex2=find(a2==-1); %Falling edges for Ag/AgCl 
%% FLEXcon, peak detection  
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prev_peak_fc=0; 
for i=1:min(length(upindex_fc),length(downindex1)) 
[amp1,indtemp1]=max(fc_hp(upindex_fc(i):downindex1(i))); 
indmax1(i)=indtemp1+upindex_fc(i)-1; 
rpeak_fc(i)=t(indmax1(i)); 
bpm_fc(i)=60./(rpeak_fc(i)-prev_peak_fc); 
prev_peak_fc=rpeak_fc(i); 
end 
%% Ag/AgCl, peak detection 
prev_peak_ag=0; 
for i=1:min(length(upindex_ag),length(downindex2)) 
[amp2,indtemp2]=max(ag_hp(upindex_ag(i):downindex2(i))); 
indmax2(i)=indtemp2+upindex_ag(i)-1; 
rpeak_ag(i)=t(indmax2(i)); 
bpm_ag(i)=60./(rpeak_ag(i)-prev_peak_ag); 
prev_peak_ag=rpeak_ag(i); 
end 
%% Peak Detection plots 
figure(6)  
plot(t, fc_hp) 
hold on; grid on; 
plot(rpeak_fc, fc_hp(indmax1),'or'); 
xlabel('Time (s)');ylabel('Voltage after BP filtering (V)'); 
title('FLEXcon ECG Waveform') 
figure(7)  
plot(t, ag_hp,'k') 
hold on; grid on; 
plot(rpeak_ag, ag_hp(indmax2),'xr'); 
xlabel('Time (s)');ylabel('Voltage after BP filtering (V)'); 
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title('Ag/AgCl ECG Waveform') 
 
Figure 6: FLEXcon Band-Pass ECG with Overlaid Peak Detection. 
 
Figure 7: Ag/AgCl Band-Pass ECG with Overlaid Peak Detection. 
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%% Cubic interpolation of R-R interval  
RR_fc=diff(rpeak_fc); %Difference in time between R-R intervals, 
FLEXcon 
RR_ag=diff(rpeak_ag); %Difference in time between R-R intervals, 
Ag/AgCl 
time_lr_fc=zeros(1,length(RR_fc)); 
time_lr_ag=zeros(1,length(RR_ag)); 
time_lr_fc(1)=0; 
for i=2:length(RR_fc) 
time_lr_fc(i)=sum(RR_fc(1:i-1)); 
end 
time_lr_ag(1)=0; 
for i=2:length(RR_ag) 
time_lr_ag(i)=sum(RR_ag(1:i-1)); 
end 
timeRR_fc=0:1/4:sum(RR_fc)-1/4; 
timeRR_ag=0:1/4:sum(RR_ag)-1/4; 
ys_fc=interp1(time_lr_fc,bpm_fc(1:length(time_lr_fc)),timeRR_fc,'spline
'); 
ys_ag=interp1(time_lr_ag,bpm_ag(1:length(time_lr_ag)),timeRR_ag,'spline
'); 
ys_fc= ys_fc-mean(ys_fc); 
ys_ag= ys_ag-mean(ys_ag); 
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Figure 8: Cubic Interpolation of Heart Rate. 
%% Power Spectral Density (PSD) 
[psd_cubic_fc,f]=pwelch(ys_fc,length(ys_fc),[],512,4); %PSD, FLEXcon 
[psd_cubic_ag,f]=pwelch(ys_ag,length(ys_ag),[],512,4); %PSD, Ag/AgCl 
psd_cubic_fc=(abs(psd_cubic_fc)).^2; 
psd_cubic_ag=(abs(psd_cubic_ag)).^2; 
 
Figure 9: Power Spectral Density. 
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4.4 Conceptual Design of Clinical Studies 
4.4.1 Phase I Design 
Note: Experiment 1 and Experiment 2 are run in parallel from subject to subject 
Subjects (on whom to perform Exp’s 1 and 2): 10 
1. Give a clinical study informational form for the subject to read and sign; obtain informed 
consent from the subject 
2. **Conduct standard pre-ECG measurement skin preparation 
For each of the 4 tested electrode types: 
Experiment 1: Measuring repositionability and skin adhesion as a function of removal force 
3. Place two electrodes on the inside forearm and record the time and date of electrode 
positioning. 
4. After electrode placement, wait 10 seconds. Then, using a string connecting the electrode 
edge or center to a weight, measure the force required to peel one electrode by the edge 
and measure the force required to pull the second electrode by its center 
5. Record the required forces and reposition the electrodes on the same region of the skin. 
6. Repeat steps (4) and (5) 8 times or until the peeling / pulling forces are too small to 
measure. 
7. Following the completion of measurements, remove these 2-electrode sets from the 
forearms. Conduct post-experiment skin sanitation procedures. 
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Experiment 2: Measuring long-term biocompatibility 
1. Place 7 FLEXcon electrodes (per electrode type) on the subject’s chest and record the 
date and time of electrode application. 
2. Every 24 hours: 
a. Remove an electrode of each type from the subject and observe the degree of skin 
irritation.  
b. Photograph the skin that was in contact with the removed electrode. 
c. Non-invasively measure the skin impedance of the skin. 
d. Ask the subject to complete a portion of a survey to describe any discomfort or 
irritation experienced within the past 24 hours. 
3. Following the completion of measurements, conduct post-experiment skin sanitation 
procedures. 
4.4.2 Phase II Design 
Number of subjects: 10 (do not have to be the same subjects tested in Phase 1, but a variety of 
skin types is still required). 
**Based on optimal Electrode iteration (1 design), test the varied storage conditions versus ECG 
quality of a single experimental electrode 
1. Give a clinical study informational form for the subject to read and sign; obtain informed 
consent from the subject 
Experiment 1: long-term ECG signal 
2. Perform standard pre-ECG measurement skin preparation 
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3. Place 3 Ag/AgCl electrodes and 3 FLEXcon electrodes on the subject’s thorax and chest 
to measure the 3-lead ECG signals. 
4. Have the subject wear two Holter monitors around the waist; one records the FLEXcon 
electrode signals, and the other records the Ag/AgCl electrode signals. 
5. Power on all electronics and make sure that all components are functional. Record the 
date and time of electrode application. 
6. After initial device activation, ask the subject to sit on a chair in the laboratory for 10 
minutes. 
7. Make sure that all the electronics are recording the ECG properly; after the 5 minutes of 
ECG acquisition, the subject can continue his or her daily activities. 
8. Before going to sleep or taking a shower, the subject must turn off the Holter monitor. 
Then, he or she must remove the Holter monitor and its leads but keep the electrodes 
attached to the skin.  
9. After waking up or taking a shower, the subject must re-attach the Holter monitor and its 
leads to the electrodes. Then, he or she must turn on the Holter monitor. 
10. Every 24 hours: 
a. The subject must come back to the laboratory and repeat steps 6 and 7.  
b. The subject must complete a portion of a survey to describe any discomfort or 
irritation experienced in the past 24 hours. 
11. Following the completion of measurements, remove these 3-electrode sets from the chest 
and collect the ECG monitoring instrumentation from the subject. Conduct post-
experiment skin sanitation procedures. 
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Experiment 2 (Performed in parallel to Experiment 1): ECG signal versus repositioning 
1. Ask the subject to sit on a chair in the laboratory and relax. 
2. Conduct proper clinical skin preparation prior to ECG electrode placement. 
3. Place an Ag/AgCl electrode and a FLEXcon electrode on the subject’s inside forearms 
and lower abdomen to measure 3-lead ECG signals. 
4. Connect the electrodes to the BIOPAC ECG collection system, initiate the system, and 
measure the subject’s ECG for 30 seconds. 
5. Measure the subject’s ECG for 6 minutes. 
6. Keeping the leads attached to the electrodes and continuing to have the BIOPAC system 
measure signals, remove each electrode from the skin for 10 seconds and then place them 
back on the original application sites. 
7. Repeat steps (5) and (6) 8 times or until the electrodes are no longer able to adhere to the 
skin. 
8. Following the completion of measurements, remove these 3-electrode sets from the 
forearms and abdomen. Conduct post-experiment skin sanitation procedures. 
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Chapter 5: Results 
5.1 Phase I: Electrode Adhesion Statistics  
Every 24 hours, the number of electrodes that fell off of each subject’s arm was recorded 
in order to quantify electrode-to-skin adhesion.  Once the total number of electrodes was 
determined, the charts were constructed using excel. The crucial fall off period of each type of 
electrode was the first four days of monitoring. These first four days gave accurate 
measurements of electrode fall off rates. The tally of electrode loss (organized by electrode 
adhesive type) is illustrated in Figures 10 and 11.  
 
 
Figure 10: Percent fallen off electrocardiogram electrodes in the first 4-days of the testing. 
 
Long Term Clinical Evaluation of Novel ECG Electrodes   
 52 
 
Figure 11: Average percent of ECG electrodes that had fallen during 7-Day testing from 10 Subjects. 
5.2 Phase I: Removal Force Data 
 The measurement of adhesion forces was designed to quantify the mechanical strength of 
an adhesive produced by FLEXcon and a standard hydrogel adhesive. The control hydrogel 
electrodes consisted of a central AgCl electrode sponge surrounded by an adhesive layer, 
whereas FLEXcon’s adhesive served as both a signal-receptive medium and an adhesive layer. 
These measurements of peeling forces and pulling forces were utilized to determine how the 
addition of a signal-transmitting functionality changes the adhesive strength of the compound. 
Table 10: Measured peak pulling forces for each of 10 subjects during the first (F1) and second (F2) removals of each electrode 
type. 
 
 
Electrode Description Subject #1 Subject #2 Subject #3 Subject #4 Subject #5 Subject #6 Subject #7 Subject #8 Subject #9 Subject #10 Average STDEV Average Force Loss
(N) (N) (N) (N) (N) (N) (N) (N) (N) (N) (N) (N) (N)
A1_F1_Pulling AGCL RIGID 24.1 16.8 20.7 19.2 18.6 15.1 20.4 15.0 11.7 29.7 19.1 5.1 13.1
A1_F2_Pulling AGCL RIGID 3.3 8.8 3.6 8.7 5.7 5.3 4.4 7.1 7.8 5.3 6.0 2.0
A2_F1_Pulling AGCL SOFT 23.3 25.8 28.8 8.7 9.2 8.1 15.9 16.9 17.1 29.1 18.3 8.2 12.9
A2_F2_Pulling AGCL SOFT 3.6 5.3 2.0 3.7 3.7 4.1 2.6 9.5 8.0 11.2 5.4 3.1
B1_F1_Pulling FLEX RIGID 14.7 28.9 34.0 21.5 10.4 21.6 26.5 26.4 20.9 26.3 23.1 6.9 18.6
B1_F2_Pulling FLEX RIGID 3.6 4.2 2.0 3.9 4.5 4.0 2.4 2.6 4.3 13.9 4.5 3.4
C1_F1_Pulling FLEX SOFT 3.5 12.6 22.3 25.4 11.1 18.3 18.6 20.5 14.9 18.0 16.5 6.3 12.9
C1_F2_Pulling FLEX SOFT 3.2 3.8 2.7 3.6 2.7 3.4 2.3 4.7 3.9 5.7 3.6 1.0
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Figure 12: Average maximum pulling force required to remove each electrode type. 
 
Fig. 13a.                           Fig. 13b.
  
Figure 13: Comparison of adhesion loss between the control and FLEXcon adhesives after repositioning, with (a) foam and (b) 
fabric body materials. 
 
Table 11: Measured peak peeling forces for each of 10 subjects during the first (F1) and second (F2) removals of each electrode 
type (in response to pulling forces). 
 
Electrode Description Subject #1 Subject #2 Subject #3 Subject #4 Subject #5 Subject #6 Subject #7 Subject #8 Subject #9 Subject #10 Average STDEV
(N) (N) (N) (N) (N) (N) (N) (N) (N) (N) (N) (N)
B3_F1_Peel AGCL RIGID 1.399 1.476 2.415 1.956 1.920 1.515 1.566 1.287 1.596 2.927 1.8 0.5
B3_F2_Peel AGCL RIGID 0.394 1.017 0.718 0.872 0.508 0.519 1.097 1.113 0.868 1.244 0.8 0.3
B2_F1_Peel FLEX RIGID 1.484 2.230 1.849 3.323 0.848 1.475 1.414 2.812 1.460 1.500 1.8 0.7
B2_F2_Peel FLEX RIGID 0.180 0.444 0.357 0.323 0.346 0.656 0.510 0.809 0.430 0.345 0.4 0.2
C2_F1_Peel FLEX SOFT 1.127 0.758 1.645 0.792 0.638 0.918 0.602 1.132 0.709 1.229 1.0 0.3
C2_F2_Peel FLEX SOFT 0.146 0.375 0.185 0.217 0.425 0.338 0.361 0.329 0.190 0.797 0.3 0.2
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Figure 14: Average maximum peeling force required to remove each electrode type. 
 
 
Figure 15: Comparison of adhesiveness losses between AgCl and FLEXcon electrodes (in response to peeling forces). 
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5.3 Phase I: Biocompatibility Experiment Results 
The data were collected every day between 10 am and 12pm. The 10 subjects visited the 
laboratory every 24 hours for 15 minutes. After each subject answered the survey that asked 
about sensational irritation (itchiness and pain), pictures were taken of his or her arms for further 
analysis. The first three types of FLEXcon electrodes (Gen. 1, Gen. 2, and Gen. 2-A) were 
placed on the left forearm; the Gen. 3 and Ag/AgCl electrodes were placed on the right forearm. 
Figure 16 below shows the locations of all 5 types of electrodes placed on forearms.  
 
Figure 16: Day 1 placement of each type of electrode; G1, G2, G2-A, G3, and Ag/AgCl inside the forearm. 
 
Pictures were taken with an iPhone5 (Apple, Inc.), which had 10 megapixel resolution, 
for observation of changes in skin coloration. The Figure 16 above shows electrode positioning 
immediately after the start of the clinical study. Figures 17-29 show the changes in skin 
G1, G2,   G2A G3,  Ag/AgCl 
Left Arm 
L 
Right Arm 
L 
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pigmentation throughout the progression of the 7-day clinical study. The Gen. 1 and Gen. 2 
adhesives caused significant skin discoloration after wearing the electrodes for 72 hours, 
indicating that the salt concentrations in both adhesive types created a high osmolalic gradient 
that drew moisture from the skin. In response to the loss of water, there was significant skin 
inflammation. Throughout the 7-day procedure, the Gen. 3 adhesive had caused little to no skin 
irritation and inflammation; however, the composition of the electrode adhesive had exhibited 
high fall-off rates and weak electrode-to-skin adhesion. Although the Gen. 2-A adhesive left a 
dry, black carbon residue after removal from each subject’s skin every day, slight changes in 
skin pigmentation were observed on the forearms of subjects 1 and 2, after 96 hours of 
experimentation. Periodic removal of the hydrogel electrodes showed no skin discoloration but 
left a clear wet residue.   
 
Figure 17: Day 2 of the testing, subjects #1 thru #10 are shown with minor irritation to the skin. 
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Figure 18: Day 3 of the study, Subjects #1 through #8 also no signs of irritation. 
 
Figure 19: Day 3 of the study, Subjects #9 and #10 also no signs of irritation. 
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Figure 20: Day 4 of the study, Subjects #1 through #6 are showing irritation on the skin. 
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Figure 21: Day 4 of the study, Subjects #7 through #10 are also showing signs of skin irritation on the skin. 
 
Figure 22: Day 5 of the study, Subjects #1 through #3 left arm skin irritation. 
 
Figure 23: Day 5 of the study, Subjects #1 through #3 right arm no signs of skin irritation. 
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Figure 24: Day 5 Subjects #5 through #10. 
 
Figure 25: Day 6 Subject #1 through #8. 
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Figure 26: Day 7 Subject #1 through #7. 
 
 
Figure 27: Day 7 Subject #8 through #10. 
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Figure 28: Day 8 Subjects #1 through #6. 
 
 
Figure 29: Day 8 Subjects #7 through #10. 
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5.4 Phase II: Short-Term Temperature Storage 
One of the FLEXcon requirements was to measure and compare the integrity of the signal 
for FLEXcon’s electrode to the hydrogel electrode (Ag/AgCl) under two extreme storage 
conditions. The two storage conditions that were chosen by FLEXcon were: 160 degrees 
Fahrenheit (F) and -80F. Another requirement was the measurement of the ECG with Ag/AgCl 
and FLEXcon electrodes after repositioning. The electrodes to be repositioned were stored at 
room temperature. The two ECG signals measured the FLEXcon and hydrogel electrodes were 
compared to determine the effect of extreme conditions on electrode performance. 
The electrodes were placed for 72 hours at 160
o
F and -80
o
F before testing. The group 
selected ten participants to participate in the study. Each individual was schedule a time to visit 
the laboratory. After the arrival of each subject, he or she was asked to be seated in order for the 
team to conduct skin preparation prior to the placement of electrodes. The heart rate monitoring 
was performed while each subject was seated in a resting position. The equipment used for ECG 
signal acquisition was a BIOPAC System (BIOPAC Systems, Inc., Model MP100), as shown in 
Figure 30. The AcqKnowledge 3.9.1 software was then used for the capture and analysis of 
ECGs measured by the Ag/AgCl and FLEXcon electrodes.  
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Figure 30: BIOPAC Systems the team used for short term signal processing under temperature storage conditions. 
5.5 Phase II: Long-Term Stationary Results 
 The long term period was decided based on the results of the biocompatibility 
experiment. Because irritation was evident after 4 days, a testing period of 96 hours was selected. 
The ECG of each subject was measured during the morning and evening hours every day. Each 
visitation was 15 minutes. The first data set was collected in morning between 9 am to 12:30 pm 
for all 10 subjects. The second data set collected was in evening between 5 pm and 9 pm. ECG 
data were collected for 15 minutes for each time in morning and evening. The ECG data were 
collected in three stages. First, subjects were asked to sit in a seat for 5 minutes and remove all 
electronic devices. Next, subjects were asked to walk around the facility for 5 minutes to analyze 
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the capability of electrodes to detect changes in heart rate and reduce motion artifact 
interference. Then, the subjects returned to a stationary, resting position for the remaining 5 
minutes. All data were uploaded subsequently to a computer and saved in a secure folder.  
 The skin preparation was done by removing shaving off any chest hair with a standard 
razor and dead skin with a standard ethyl alcohol pad. Skin preparation was done in order to 
maximize initial skin-to-electrode adhesion. 
The five-lead electrode configuration was utilized to measure each subject’s ECG. 
FLEXcon electrodes were placed next to Ag/AgCl electrodes for simultaneous, real-time 
comparison.  
  Table below shows the data calculated with MATLAB for day 1. The average of those 
data was calculated. The comparison of FLEXcon electrodes and Ag/AgCl electrodes, 
correlation coefficient was done based on table below for each of heart rate variability. All 
correlation of each data analysis were plotted on graphs with FLEXcon values on vertical axes 
and Ag/AgCl on horizontal axes. The slope of line that fit all the data shows the correlation 
coefficient, which means the percentage that those data are equal with each other.  
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Table 12: Heart Rate Variability (HRV) Analysis for Day 1 
 
 
 
 
Subject # fc_Found fc_fixed ag_found ag_Fixed LF_fc LF_ag HF_fc HF_ag
1 194 1 194 0 8.57E+04 8.43E+04 6.76E+03 7.56E+03
2 166 1 166 0 1.57E+04 2.80E+04 1.75E+04 1.83E+04
3 180 0 180 0 4.15E+04 8.65E+03 8.76E+05 9.83E+03
4 190 4 190 0 3645100 3665800 104080 99705
5 140 0 140 0 7.45E+04 7.51E+04 4.09E+04 4.08E+04
6 176 2 176 0 2.04E+05 2.09E+05 7.78E+03 6.21E+03
7 175 0 175 0 3.39E+05 3.32E+05 2.77E+04 3.30E+04
8 148 0 148 0 5.16E+06 5.16E+06 3.06E+05 2.91E+05
9 174 0 174 0 5.06E+05 5.03E+05 3.00E+04 3.00E+04
10 146 0 146 0 1.18E+06 1.19E+06 7.83E+03 7.73E+03
Average 1.13E+06 1.13E+06 1.42E+05 5.44E+04
Subject # mean_bpm_fcmean_bpm_agstd_bpm_fc std_bpm_ag RMSSD_fc RMSSD_ag SDNN_fc SDNN_ag
1 97.6225 97.8936 3.7941 5.1215 0.0134 0.0127 0.0242 0.0241
2 84.0144 83.5636 7.7474 4.8048 0.0246 0.0244 0.0416 0.0414
3 92.5277 91.1347 15.6057 10.5548 0.1405 0.0357 0.0877 0.03
4 95.8946 96.5097 7.2717 10.4417 0.0304 0.0303 0.0501 0.0494
5 70.6575 70.6433 5.4852 5.4482 0.055 0.055 0.0649 0.0649
6 89.2752 88.7258 8.0084 10.572 0.0228 0.0226 0.0416 0.0415
7 88.9117 89.1536 15.9128 18.9866 0.0283 0.0288 0.0476 0.0475
8 77.3088 77.1561 25.2158 23.509 0.076 0.0757 0.1038 0.1038
9 87.7624 87.7759 5.7345 5.7139 0.0253 0.025 0.0454 0.0452
10 74.3527 74.0289 7.4636 6.737 0.0383 0.0382 0.0731 0.0732
Average 85.83275 85.65852 10.22392 10.18895 0.04546 0.03484 0.058 0.0521
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Figure 31: Correlation of Mean Heart Rate for FLEXcon and Ag/AgCl Day 1. 
 
Figure 32: Correlation of Low Frequency for FLEXcon and Ag/AgCl, Day 1. 
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Figure 33: Correlation of High Frequency for FLEXcon and Ag/AgCl Day 1. 
 
Figure 34: Correlation of STD of Mean Heart Rate for FLEXcon and Ag/AgCl Day 1. 
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Figure 35: Correlation of RMSSD for FLEXcon and Ag/AgCl Day 1. 
 
Figure 36: Correlation of SDNN for FLEXcon and Ag/AgCl Day 1. 
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 The second day of the long term of the experiment most of the electrodes still adhered to 
the subjects’ skin after each subject had taken a shower. Table 13 below shows all data measured 
on day 2 after analysis of heart rate variability. In order to compare both types of electrodes, the 
average of all heart rate measurements and the correlation coefficient (FLEXcon on vertical axes, 
Ag/AgCl on horizontal axes) for each metric were calculated.  The correlation coefficient is the 
slope that both types of electrodes. 
Table 13: HRV Analysis for Day 2. 
 
 
Subject # fc_Found fc_fixed ag_found ag_Fixed LF_fc LF_ag HF_fc HF_ag
1 180 0 180 0 1.56E+06 1.57E+06 1.86E+04 1.90E+04
2 162 0 162 0 3.39E+06 3.46E+06 1.80E+04 1.52E+04
3 142 0 142 0 4.19E+04 3.92E+04 1.94E+04 2.01E+04
4 188 7 188 1 5.79E+05 5.73E+05 2.80E+05 2.51E+05
5 147 1 147 0 6.49E+05 6.41E+05 3.32E+04 3.49E+04
6 161 0 161 0 1.05E+05 1.05E+05 3.78E+03 3.56E+03
7 174 0 174 0 4.14E+05 4.27E+05 1.07E+04 1.07E+04
8 149 0 149 0 1.32E+06 1.28E+06 8.13E+04 8.56E+04
9 167 0 167 0 3.10E+05 3.18E+05 6.98E+03 7.25E+03
10 171 0 171 0 1.06E+07 1.01E+07 1.69E+05 1.49E+05
Average 1.89E+06 1.85E+06 6.40E+04 5.96E+04
Subject # mean_bpm_fcmean_bpm_agstd_bpm_fc std_bpm_ag RMSSD_fc RMSSD_ag SDNN_fc SDNN_ag
1 92.6201 92.7259 28.8701 30.4293 0.0207 0.0209 0.0433 0.0433
2 83.5677 83.3017 27.0255 22.8211 0.0279 0.0281 0.0605 0.0605
3 71.7702 71.3252 5.7142 3.316 0.031 0.0322 0.04 0.0379
4 96.2296 95.0922 15.415 10.2059 0.0227 0.022 0.0642 0.0633
5 74.4689 74.6585 7.018 7.8959 0.0516 0.0517 0.074 0.074
6 82.8913 82.7336 24.7182 22.7581 0.0268 0.027 0.0533 0.0535
7 87.5594 87.9317 5.9443 7.2144 0.0247 0.0249 0.0472 0.0473
8 75.4804 75.4513 7.7833 7.7419 0.0443 0.0438 0.0833 0.0831
9 84.248 84.2753 4.8402 4.9214 0.0196 0.0196 0.0404 0.0405
10 86.6588 86.8524 8.3679 8.6896 0.0503 0.0504 0.0737 0.0738
Average 83.54944 83.43478 13.56967 12.59936 0.03196 0.03206 0.05799 0.05772
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Figure 37: Correlation of Mean Heart Rate for FLEXcon and Ag/AgCl Day 2. 
 
Figure 38: Correlation of Low Frequency for FLEXcon and Ag/AgCl, Day 2. 
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Figure 39: Correlation of High Frequency for FLEXcon and Ag/AgCl Day 2. 
 
Figure 40: Correlation of STD of Mean Heart Rate for FLEXcon and Ag/AgCl Day 2. 
0 0.5 1 1.5 2 2.5 3
x 10
5
-0.5
0
0.5
1
1.5
2
2.5
3
3.5
x 10
5Correlation  between Flexcon and Ag/AgCl of High Frequency Day 2 at Rest
F
L
E
X
c
o
n
 V
a
lu
e
Ag/AgCl value
 
 
data 1
   linear
0 5 10 15 20 25 30 35
0
5
10
15
20
25
30
35
40
Correlation  of Standard Deviation of Heart rate between Flexcon and Ag/AgCl Day 2 at Rest
F
L
E
X
c
o
n
 V
a
lu
e
Ag/AgCl value
 
 
data 1
   linear
Slope = 0.8919 
 
 
 
 
 
 
 
 
Slope = 0.9832 
 
 
 
 
 
 
 
 
 
Long Term Clinical Evaluation of Novel ECG Electrodes   
 73 
 
Figure 41: Correlation of RMSSD for FLEXcon and Ag/AgCl Day 2. 
 
Figure 42: Correlation of SDNN for FLEXcon and Ag/AgCl Day 2. 
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 All the data were collected for each subjects after the monitoring the skin and adhesion of 
both types of electrodes. Subject 1, 2, 3, 5, 7, 8, and 10 did not had any problem with electrodes 
fallen off and neither for skin iteration or itchiness. Subject 4 had extremely itchiness from all 
electrodes. All electrodes were reposition in order to reduce itchiness and for data recording. 
After, all electrodes were taped with adhesive with holes in order for the skin to breathe. Subject 
6 had extremely itchy skin from all electrodes. All electrodes were reposition in order to allow 
irritated skin to breath.  Subject 9 had unbearable skin iteration and all electrodes were reposition 
in order to allow the irritated skin to breath. After, all electrodes were taped in order to collect 
data.  Table below shows all the data collected for heart rate variability measurements for 
analysis. The average was calculated and then the coefficient correlation graphs with their slope.  
Table 14: HRV Analysis for Day 3. 
 
 
Subject # fc_Found fc_fixed ag_found ag_Fixed LF_fc LF_ag HF_fc HF_ag
1 160 0 160 0 2.94E+05 3.18E+05 1.06E+04 1.07E+04
2 133 0 133 0 5.09E+04 4.85E+04 9.85E+04 9.54E+04
3 139 0 139 0 3.66E+11 5.71E+13 7.46E+13 2.33E+16
4 162 2 162 0 3.92E+05 4.10E+05 5.86E+03 6.31E+03
5 172 0 172 0 1.78E+06 1.80E+06 4.86E+04 4.66E+04
6 164 0 164 0 2.78E+05 2.76E+05 6.23E+03 6.79E+03
7 172 0 172 0 1.25E+06 1.27E+06 1.42E+04 1.46E+04
8 150 0 150 0 3.39E+06 3.27E+06 8.15E+04 8.67E+04
9 182 0 182 0 4.16E+05 4.35E+05 1.95E+04 1.60E+04
10 153 0 153 0 1.38E+05 1.37E+05 3.13E+03 2.57E+03
Average 3.66E+10 5.71E+12 7.46E+12 2.33E+15
Subject # mean_bpm_fcmean_bpm_agstd_bpm_fc std_bpm_ag RMSSD_fc RMSSD_ag SDNN_fc SDNN_ag
1 80.5103 81.33 7.3191 7.2245 0.0242 0.0242 0.0416 0.0419
2 67.8233 67.3478 4.0869 4.3922 0.0589 0.0591 0.0584 0.0587
3 107.8288 108.7619 7.932 6.5501 0.1218 0.1092 0.0937 0.0909
4 81.7915 81.4805 6.9869 4.8585 0.0326 0.034 0.0441 0.0444
5 87.9018 87.9973 11.1031 11.1095 0.0421 0.0418 0.0899 0.0899
6 82.8127 82.9523 9.216 10.7078 0.0277 0.0275 0.0488 0.0488
7 87.6696 88.1649 12.1513 15.9898 0.0364 0.0359 0.0839 0.0836
8 76.1319 76.587 8.1209 11.8667 0.0436 0.0435 0.0707 0.0708
9 91.9618 91.6926 7.6614 5.3623 0.0218 0.0201 0.0382 0.0378
10 78.3901 78.3655 11.5837 11.4098 0.0326 0.0325 0.0966 0.0965
Average 84.28218 84.46798 8.61613 8.94712 0.04417 0.04278 0.06659 0.06633
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Figure 43: Correlation of Mean Heart Rate for FLEXcon and Ag/AgCl Day 3. 
 
Figure 44: Correlation of Low Frequency for FLEXcon and Ag/AgCl, Day 3. 
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Figure 45: Correlation of High Frequency Signal Power for FLEXcon and Ag/AgCl Day 3. 
  
Figure 46: Correlation of STD of Mean Heart Rate for FLEXcon and Ag/AgCl Day 3. 
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As shown in Figure 46, there was a significant difference between the FLEXcon and 
hydrogel measurements of HRV. The value of the correlation coefficient (0.5480) shows that the 
variation of heart rate measured by the Ag/AgCl electrodes was approximately two times that 
measured by the FLEXcon electrodes. Because the subjects were in relaxed and resting positions 
during data acquisition, their heart rates were stable with average deviations of 8.62 (FLEXcon) 
and 8.94 (hydrogel) beats per minute (Table 14). This increase in measured heart rate standard 
deviation suggests that the precision of peak detection in the algorithm has decreased during 
calculations of R-R intervals in the Ag/AgCl ECG waveform. The indexing of peak locations on 
the QR or RS complexes, instead of the R wave itself, was the most likely cause of larger heart 
rate variances. 
 
Figure 47: Correlation of RMSSD for FLEXcon and Ag/AgCl Day 3. 
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Figure 48: Correlation of SDNN for FLEXcon and Ag/AgCl, Day 3. 
 The day 4 of the experiment for long term stationary electrodes were taped for all 10 
subjects in order to keep them on place for better data recording. Subject 4 had to reposition all 
electrodes because skin was burning and had sensations. After making sure all electrodes were 
on place and had good conduction with skin, data recording started for 15 minutes.  
   Table below shows all data measurements for day 4 or after 72 hours. Subject 10 was not 
placed on table below because the Ag/AgCl measurements were very bad and FLEXcon were 
good. In order to compare both data with similarities the entire data for subject 10 was removed 
and compare both types of electrodes with nine subjects. The average was calculated as it is 
shown on table below and correlation coefficient was done between FLEXcon electrodes and 
Ag/AgCl electrodes.  
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Table 15: HRV Analysis for Day 4. 
 
 
 
Figure 49: Correlation of Mean Heart Rate for FLEXcon and Ag/AgCl, Day 4. 
Subject # fc_Found fc_fixed ag_found ag_Fixed LF_fc LF_ag HF_fc HF_ag
1 165 0 165 0 3.31E+05 3.29E+05 2.99E+04 2.98E+04
2 163 0 163 0 5.90E+05 6.84E+05 9.85E+03 2.01E+04
3 151 0 151 0 5.33E+04 4.12E+04 3.31E+05 1.17E+04
4 213 2 213 5 2.29E+06 2.18E+06 7.37E+04 6.55E+04
5 213 2 213 5 2.29E+06 2.18E+06 7.37E+04 6.55E+04
6 144 0 144 0 1.13E+05 1.13E+05 1.18E+04 1.09E+04
7 163 0 163 0 1.83E+06 1.82E+06 4.27E+04 4.20E+04
8 135 0 135 0 8.89E+05 8.89E+05 1.97E+05 2.00E+05
9 182 0 182 0 5.00E+05 5.06E+05 6.47E+03 6.14E+03
10
Average 9.87E+05 9.71E+05 8.62E+04 5.02E+04
Subject # mean_bpm_fcmean_bpm_agstd_bpm_fc std_bpm_ag RMSSD_fc RMSSD_ag SDNN_fc SDNN_ag
1 83.7658 83.6528 10.7085 9.5903 0.0313 0.0308 0.0545 0.0545
2 82.2916 84.3751 5.805 8.4912 0.0275 0.0272 0.0522 0.0522
3 77.9508 77.2174 6.919 7.901 0.0863 0.0445 0.0605 0.0431
4 107.5271 107.2472 10.0532 7.751 0.0172 0.0178 0.0411 0.0411
5 107.5271 107.2472 10.0532 7.751 0.0172 0.0178 0.0411 0.0411
6 73.2103 73.1188 11.255 10.3622 0.0428 0.0422 0.064 0.0639
7 82.7782 82.7461 9.4426 9.1954 0.0399 0.0388 0.0646 0.0644
8 68.7481 68.8141 8.1607 8.431 0.0719 0.0718 0.0989 0.099
9 91.882 91.8806 4.7078 4.693 0.0187 0.0184 0.0333 0.0332
10
Average 86.1867778 86.2554778 8.56722222 8.24067778 0.0392 0.03436667 0.05668889 0.05472222
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Figure 50: Correlation of Low Frequency for FLEXcon and Ag/AgCl, Day 4. 
 
Figure 51: Correlation of High Frequency for FLEXcon and Ag/AgCl Day 4. 
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Figure 52: Correlation of STD of Mean Heart Rate for FLEXcon and Ag/AgCl, Day 4. 
 
Figure 53: Correlation of RMSSD for FLEXcon and Ag/AgCl Day 4. 
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Figure 54: Correlation of SDNN for FLEXcon and Ag/AgCl Day 4. 
 
 The end of long term experiment is day 5 or after 96 hours. All electrodes were taped for 
all 10 subjects because the adhesion was not strong any more. After making sure that all 
electrodes had good conduction with skin data recording started for the last 15 minutes. At the 
end all electrodes were removed from 10 subjects and observed the skin. Pictures were taken 
after electrode removal. The pictures below shows the skin iteration and redness after 5 days of 
96 hours. The subject below have the most skin iteration than other subjects. The adhesion of 
electrodes stuck on skin was removed with adhesive removal and clean the skin with alcohol 
pads. All the subjects were thanked for their participation on all experiments the MQP team 
designed.  
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Table 16: HRV Analysis for Day 5. 
 
 
 
Figure 55: Correlation of Mean Heart Rate for FLEXcon and Ag/AgCl Day 5. 
Subject # fc_Found fc_fixed ag_found ag_Fixed LF_fc LF_ag HF_fc HF_ag
1 193 0 193 0 1.09E+06 1.09E+06 2.54E+04 2.49E+04
2 162 0 162 0 8.23E+04 8.15E+04 4.37E+03 4.33E+03
3 136 0 136 0 6.85E+03 7.21E+03 1.74E+04 2.02E+04
4 166 0 166 5 2.46E+04 2.48E+04 3.05E+04 2.93E+04
5 175 0 175 8 2.44E+05 2.44E+05 5.13E+03 5.31E+03
6 172 6 172 2 2.76E+05 2.65E+05 3.81E+04 3.34E+04
7 156 0 156 0 3.30E+05 3.32E+05 9.59E+03 9.43E+03
8 166 0 166 0 2.32E+06 2.38E+06 2.02E+05 2.13E+05
9 169 0 169 1 2.00E+05 2.02E+05 500.9089 527.6969
10 193 0 193 0 8.86E+05 8.77E+05 1.27E+03 1.23E+03
Average 5.45E+05 5.50E+05 3.34E+04 3.42E+04
Subject # mean_bpm_fcmean_bpm_agstd_bpm_fc std_bpm_ag RMSSD_fc RMSSD_ag SDNN_fc SDNN_ag
1 97.7743 97.7156 10.319 9.7049 0.0211 0.0213 0.0426 0.0426
2 81.8904 81.8599 7.7189 7.4813 0.0247 0.0243 0.0464 0.0464
3 70.1592 70.3568 21.685 22.7569 0.0382 0.0663 0.0469 0.0566
4 83.6781 83.6628 4.3046 4.3081 0.0353 0.0347 0.0396 0.0394
5 88.4267 88.4206 7.6698 7.6804 0.0206 0.0211 0.048 0.0481
6 86.8257 86.8165 5.2697 5.1134 0.0225 0.0224 0.0354 0.0352
7 78.9696 79.0672 9.6918 10.6845 0.0393 0.039 0.0596 0.0596
8 85.7377 86.1563 25.7153 30.9093 0.0375 0.0374 0.0691 0.069
9 84.8649 84.8637 4.1552 4.143 0.0163 0.0158 0.0325 0.0324
10 97.0086 96.9953 5.3153 5.2431 0.0106 0.011 0.0273 0.0273
Average 85.53352 85.59147 10.18446 10.80249 0.02661 0.02933 0.04474 0.04566
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Figure 56: Correlation of Low Frequency for FLEXcon and Ag/AgCl, Day 5. 
 
 
Figure 57: Correlation of High Frequency for FLEXcon and Ag/AgCl Day 5. 
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Figure 58: Correlation of STD of Mean Heart Rate for FLEXcon and Ag/AgCl Day 5. 
 
Figure 59: Correlation of RMSSD for FLEXcon and Ag/AgCl Day 5. 
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Figure 60: Correlation of SDNN for FLEXcon and Ag/AgCl Day 5. 
 Heart rate variability was analyze for each day for all 5 days. Also, at the end of day 5 of 
data analysis, it was done the HRV for all 5 days together. The correlation coefficient for entire 
data analysis are on last row of table below. Graphs for each variable were plotted, where 
FLEXcon values are on vertical axes and Ag/AgCl are on horizontal axes.  
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Table 17: Correlation Coefficient of HRV Analysis over period of 5 days. 
 
Correlation Coefficients for HRV       
 
Mean_BPM LF HF std_PBM RMSSD SDNN 
Day1 Rest 0.98978 0.99726 0.9467 0.9557 0.973 0.735 
Day2 Rest 0.9894 0.9826 0.8919 0.9832 1 0.9867 
Day3 Rest 0.97621 0.9635 0.95379 0.31166 0.9782 1 
Day4 Rest 0.99569 0.9684 0.93799 0.29413 0.8455 0.934 
Day5 Rest 0.99285 0.97768 0.939 0.83322 0.5487 0.93 
5 Days at Rest 0.99651 1 0.933 0.76087 0.97716 0.9 
 
 
Figure 61: Correlation of Mean Heart Rate for FLEXcon and Ag/AgCl for 5 days. 
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Figure 62: Correlation of Low Frequency for FLEXcon and Ag/AgCl, for 5 days. 
 
Figure 63: Correlation of High Frequency for FLEXcon and Ag/AgCl for 5 days. 
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Figure 64: Correlation of STD of Mean Heart Rate for FLEXcon and Ag/AgCl for 5 days. 
  
 
Figure 65: Correlation of RMSSD for FLEXcon and Ag/AgCl for 5 days. 
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Figure 66: Correlation of SDNN for FLEXcon and Ag/AgCl for 5 days. 
5.6 Phase II: Motion Artifact 
During the long-term measurement of the subjects’ ECGs, the subjects were required to 
remain seated, in a resting position, for five minutes. Then, the subjects were asked to walk 
around the facility for five minutes. Changes in ECG signal quality were measured via two 
methods: peak detection and Discrete Fourier Transform (DFT) analyses. Arbitrary 2-minute 
segments of the ECG during motion were analyzed.  
The designed peak detection algorithm was utilized to count the number of QRS 
complexes; however, motion artifacts affected the quality of the ECG traces, causing 
misdetections. 
  Although the peak detection algorithm provided a concrete metric of electrode performance 
during resting, neither peak detection nor visual inspection could effectively facilitate the 
distinguishing of QRS complexes in traces that were affected by large-amplitude noise. 
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Therefore, the DFT was utilized as a secondary measure to analyze changes in signal quality. 
Because the Holter monitors sampled the human ECGs at 180 samples per second, the DFT was 
mapped to frequencies between 0 and 90 Hz.  
 
 
Figure 67: Time-domain and DFT analysis of a randomly selected human subject’s ECG within 12 hours after initial electrode 
application. 
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Figure 68: Time-domain and DFT analysis of a randomly selected human subject’s ECG when stationary (top) and in motion 
(bottom), between 24 and 36 hours after initial electrode application. 
 
 
Figure 69: Time-domain and DFT analysis of a randomly selected human subject’s ECG when stationary (top) and in motion 
(bottom), between 48 and 60 hours after initial electrode application. 
 
Long Term Clinical Evaluation of Novel ECG Electrodes   
 93 
 
Figure 70: Time-domain and DFT analysis of a randomly selected human subject’s ECG when stationary (top) and in motion 
(bottom), between 72 and 90 hours after initial electrode application. 
 
 
Figure 71: Time-domain and DFT analysis of a randomly selected human subject’s ECG when stationary (top) and in motion 
(bottom), 96 hours after initial electrode application. 
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Chapter 6: Discussion 
6.1 Introduction  
 Following experimentation, the first clinical study produced a variety of statistical, 
mechanical, and biomaterial results to characterize the strength and biocompatibility of 
FLEXCon’s experimental adhesives. These experiments were designed to simultaneously 
characterize these measures generated by commercially available hydrogel electrodes, to provide 
a baseline performance benchmark. 
6.2 Electrode Biocompatibility Analysis  
The electrodes that had fallen off varied from subject to subject due to the adhesion 
between the skin tissue and the electrode. The Gen. 2-A electrode exhibited the strongest skin-to 
electrode adhesion. This electrode outperformed all the other types because only 2.5% had fallen 
off in the first four days, and only 7.14% had fallen off throughout the entire experiment, as 
shown in Figure 11. The Gen. 1 and Gen. 2 types showed stronger adhesion than that of the 
Ag/AgCl; however, Gen. 1 and Gen.2 caused severe skin irritation. Although Gen. 3 caused little 
to know skin irritation, it had the weakest adhesion to the skin. 
The results of the long-term biocompatibility experiment (as shown in Figure 11) 
demonstrate that the G2-A adhesive was a superior option for further testing in Phase II. G2-A’s 
skin adhesion data shows that it outperforms all types and the currently available on the market 
Silver/Silver Chloride (Ag/AgCl) by 43%.   
6.3 Removal Force Analysis  
 During the force test, one FLEXcon was adhesive was compared to the AgCl hydrogel. 
These adhesive mediums were attached to two types of electrode body materials, cloth and 
polypropylene foam, to characterize the relationship between adhesion strength and electrode 
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body material type as well as compare the retention of adhesive strengths of FLEXcon’s SRM 
and a standard adhesive after repositioning. These two primary metrics were measured for both 
pulling and peeling forces.  
 The pulling force experiment was designed to replicate ECG lead tugging forces that are 
caused by patient or equipment movement and compare the Ag/AgCl and FLEXcon adhesives’ 
resistances to these forces. The mechanical force profile of these trials each showed the 
escalation to a single maximum force just before a rapid drop to zero, indicating the threshold 
force required to pull the electrode from the subject’s skin. In the cases of both adhesive types, 
the rigidity and thickness of the adhesive affected overall resistance to tensile forces, as shown in 
Figure 12. The foam provided more mechanical stability for the adhesive, increasing the 
threshold removal force. As demonstrated in Figure 13, attached to the rigid foam body, the 
FLEXcon Adhesive required a larger removal force than that of the control adhesive; however, 
after repositioning, the FLEXcon adhesive was removed more easily. Attached to the soft fabric 
material, both the FLEXcon and control adhesives experienced equivalent losses in adhesive 
resistance. 
 Next, the force required to peel the electrode from the skin was measured. Unlike the 
pulling force profile, the peeling force measurement showed two maxima separated by a local 
minimum. The second maxima was immediately followed by a quick decrease to zero, indicated 
complete removal of the electrode from the skin. The first maximum was the force measurement 
of interest because it indicated the force necessary to overcome the adhesive bond between the 
entire electrode surface and the skin. Figure 14 shows that the forces required to peel the 
electrode is much smaller than that required to pull the electrode. The use of the fabric and foam 
bodies with the FLEXcon electrode further illustrated how more rigid materials provide more 
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support to a given adhesive. The Ag/AgCl electrode samples (attached to the foam material) 
provided an adhesion performance benchmark for comparison between experimental and 
commercially available adhesives. Although the performance index (control: experimental) was 
approximately one during the first removal, this ratio doubled after the second peel, indicating a 
decrease in the FLEXcon adhesive’s strength, relative to that of the commercial adhesive (Figure 
15). Therefore, the control adhesive maintains more of its adhesive integrity after repositioning.  
 This force study addressed factors that could cause complications during clinical 
implementation of the FLEXcon electrodes. Environmental factors and human error cause the 
removal or repositioning of the electrode. The pulling force experiment allowed the group to 
determine that the experimental adhesive is highly resistive to tensile forces that are present in 
dynamic environments. However, the adhesive loses approximately 80.5% of its mechanical 
strength after the first removal.    
6.4 Storage Temperature and Electrode Performance 
A three minute ECG signal was recorded for each subject. Figure 67 displays the average 
heart rate for all ten subjects. At 160 Fahrenheit the integrity of the signal for FLEXcon’s 
electrode showed the same heart rate detection as the hydrogel with an average of 80.3 beats per 
minute (bpm). As well as the -80 Fahrenheit at 79.8 bpm. The results of the collected data before 
and after repositioning highlighted that the FLEXcon electrode had the same measured heart rate 
as the hydrogel and the rectitude of the signal was not compromised.  
Further statistical variables and analyses for the collected data were performed by 
calculating the power spectral density (PSD) of both signals. From these PSD plots, the low-
frequency signal powers (LF), high-frequency signal powers (HF) were calculated. In the time 
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domain, the root mean squared of standard deviation (RMSSD) and the standard deviation of R-
R interval time length (SDNN) were used to determine the variance of heart rate.  
 
Figure 72: Average heart rate for ten subject. 
The Root Mean Square of the Successive Differences it’s an important tool in looking 
into the time domain in order distinguish the heart rate variability, and the RMSSD will allow us 
to look into the successive differences between the intervals of the two signals and compare 
them. Figure 68 shows the statistics of our data for RMSSD. Looking into 160
o
F and -80
o
F the 
calculated results manifest that the difference between the two signals is only 1%. This value is 
negligent since the detected heart rate would not have a significant difference in the measured 
heart rate. In Reposition 1 (R1) and Reposition 2 (R2) for the room-temperature electrodes the 
RMSSD statistical values highlights the equivalent values for hydrogel and FLEXcon. 
 
   Ag/AgCl    FlexCon    Ag/AgCl    FlexCon    Ag/AgCl    FlexCon    Ag/AgCl    FlexCon
Series1 79.5 79.5 79 79 87.2 87.2 80.1 80.1
72.0
74.0
76.0
78.0
80.0
82.0
84.0
86.0
88.0
90.0
H
ea
rt
 R
at
e 
Heart Rate Average over Ten Subjects 
       -80˚ F      +160 ˚ F 
Reposition 1 
Reposition 2 
Long Term Clinical Evaluation of Novel ECG Electrodes   
 98 
 
Figure 73: Statistical results for the root mean square for the successive differences. 
Another important statistical comparison of the signal is the Low-Frequency and High-
Frequency signal power. The heart rate variability (HRV) spectrum contains two major 
components, the high frequencies (0.14-0.40 Hz; P = 0.0002) and low frequencies (0.05-0.14 Hz; 
P = 0.0001) components. Using our designed algorithm we were able to filter the two signals and 
compare the FLEXcon LF and HF to those of the hydrogel. The statistical results show that both 
signals share the same results across all three short-term studies.   
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Figure 74: Statistical results for the High-Frequency signal power. 
 
 
Figure 75: Statistical results for the Low-Frequency signal power. 
3.65E+04 3.62E+04 
5.05E+04 4.80E+04 
8.26E+04 8.26E+04 
4.09E+04 4.28E+04 
0.00E+00
1.00E+04
2.00E+04
3.00E+04
4.00E+04
5.00E+04
6.00E+04
7.00E+04
8.00E+04
9.00E+04
1.00E+05
   Ag/AgCl    FlexCon    Ag/AgCl    FlexCon    Ag/AgCl    FlexCon    Ag/AgCl    FlexCon
(+160 Fahrenheit) (-80 Fahrenheit)       Reposition 1      Reposition 2
High-Frequency Signal Power 
7.42E+05 7.41E+05 
1.14E+06 1.13E+06 
3.53E+06 3.53E+06 
3.92E+05 3.93E+05 
-5.00E+05
0.00E+00
5.00E+05
1.00E+06
1.50E+06
2.00E+06
2.50E+06
3.00E+06
3.50E+06
4.00E+06
4.50E+06
   Ag/AgCl    FlexCon    Ag/AgCl    FlexCon    Ag/AgCl    FlexCon    Ag/AgCl    FlexCon
(+160 Fahrenheit) (-80 Fahrenheit)       Reposition 1      Reposition 2
W
at
t 
Low-Frequency Signal Power 
Long Term Clinical Evaluation of Novel ECG Electrodes   
 100 
Statistics for the standard deviation for the heart rate are shown below in Figure 71. In 
our analysis for the storage conditions and repositioning of the hydrogel and FLEXcon 
electrodes we can conclude that there is no statistical difference in the integrity of the signal. 
Both types of electrodes show no significant difference in the signal performance and heart rate 
detection without the concession of its functionality of the ECG. Furthermore, both types of 
electrodes show convincing results based on the signal performance and their functionality. An 
ECG signal is shown in Figure 71 below.  Looking into the QRS complex wave of the two 
signals it was determined that the FLEXcon electrode is comparable to the hydrogel not only by 
looking into heart rate but also analyzing the statistical results of our data.  
 
 
Figure 76: Statistical results for the Standard Deviation of heart rate. 
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6.5 Long-Term Resting ECG 
 Long term experiment was conducted over 5 days or 96 hours. This period of time was 
chosen from the results of Phase I. The correlation coefficient for all 5 days and for entire period 
of experiment are shown at table above. It is worth to mention the correlation coefficients for 
entire period. The mean heart rate is at 99.65 %. This result reflects a strong similarity between 
the FLEXcon and hydrogel signals. Low frequency LF of heart rate is at 100%, a perfect 
comparison. The correlation coefficients between the FLEXcon and hydrogel heart rate variance, 
high-frequency signal power, and SDNN were greater than 95%, demonstrating high correlation 
between the two electrodes.  
6.6 Investigating Motion Artifact 
The utilization of the DFT and peak detection algorithm showed changes in signal quality 
during long-term clinical ECG measurement. Throughout the progression of the clinical 
measurement, the ECGs measured by both FLEXcon and Ag/AgCl electrodes had defined QRS 
complexes. Figure 62 shows that shortly after electrode application, the signal quality in both the 
time and frequency domains are identical while the subject was at rest. The P, QRS, and T 
complexes are clearly defined in the time domain. In the frequency domain, both FLEXcon and 
hydrogel waveforms have three harmonic peaks in the 1-5 Hz band. The low-frequency content 
of the ECG signal is separated from the higher-frequency noise by a lower-amplitude valley 
within the 6-8 Hz band. During motion, both the FLEXcon and hydrogel signal DFTs reflect the 
removal of this valley, the increase in background noise bandwidth and amplitude, as well as the 
reduction of the signal-to-noise ratio between the three harmonic ECG peaks and the background 
noise. However, these artifacts are not large enough to cause significant distortion of any of the 
ECG waves in the time domain.  
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 Twenty-four hours after initial electrode placement, stationary ECG measurement still 
exhibited clear waveform definition, as shown by three DFT peaks, between 1 and 5 Hz, with 
amplitudes significantly above noise level (in Figure 63). However, motion introduced 
significant 9-Hz and 10-Hz artifacts in both FLEXcon and hydrogel measurements. As a result, 
both ECGs exhibited low-amplitude and high-frequency fluctuations in the P and T waves and 
retained QRS complex definition. 
 Fourier analysis of ECG signals 48 hours after the start of the experiment showed further 
definition of motion artifact interference in both FLEXcon and hydrogel measurements. Figure 
64 demonstrates the formation of 5 higher-frequency (8-15 Hz) noise maxima of magnitudes 
comparable to those of the signal peaks (1-5 Hz). This formation of larger-amplitude, higher-
frequency motion artifacts resulted in the increase in P wave amplitude and the decrease in T 
wave amplitude.  
 Seventy-two hours after electrode application, the P and T waves were defined by 
distorted during the resting measurement. A single artifact at 10 Hz was evident above 
background noise level in both stationary measurements. However, during motion, low-
frequency distortion in the FLEXcon signal caused further increase in P wave amplitude and the 
reduction of T wave amplitude. The ECG measured by the hydrogel electrodes exhibited 
significant low-frequency interference – in the time domain, there was little to no P and T wave 
definition. The hydrogel electrodes exhibited high sensitivity to 60-Hz power line interference, 
whereas the FLEXcon ECG did not (Figure 65).  
 Lastly, after 90 hours of use, the FLEXcon electrodes maintained QRS complex 
definition with some distortion of the P and T waves. In contrast, the hydrogel electrodes 
produced significant high-frequency noise artifacts during resting measurements. In the 
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stationary hydrogel ECG signal, the P and T waves were indistinguishable (Figure 66). During 
motion, sensitivity of the hydrogel to low-frequency baseline wander is evident in both the time 
and frequency domains; the motion of the subject caused power rail saturation, completely 
distorting the entire ECG waveform. 
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Chapter 7: Final Design and Validation 
7.1 Introduction 
Atrial fibrillation is a common form of cardiac arrhythmia that results in rapid, weak 
atrial quivering. The inability of the atria to deliver blood to the ventricles can result in the 
clotting of stagnant blood and subsequent onset of stroke. This cardiac abnormality is common in 
the United States and becomes more frequent with increasing age (Centers for Disease Control 
and Prevention, 2013). In 1998, an estimated 2.2 million Americans were diagnosed with 
intermittent atrial fibrillation; in conjunction with pre-existing health complications, such as high 
blood pressure, diabetes, and histories of smoking, atrial fibrillation can cause death or serious 
internal injury (Benjamin et al, 1998).  
 Because atrial fibrillation is an intermittent disease, long-term electrocardiogram (ECG) 
measurement is necessary to detect potentially life-threatening episodes. In recent years, 
innovations in electronics, adhesives, and algorithm designs have contributed to the 
improvement of long-term cardiac monitoring systems. Noninvasive ECG measurement 
eliminates the risk of infection or injury; however, the measurement of the ECG on the surface of 
the skin introduces sensor-to-skin motion artifacts and environmental interference. Devices use 
analog amplification and filtering techniques to eliminate these different types of artifacts and 
facilitate ambulatory ECG measurement (Goette et al, 2011). The limited precision of analog 
components can allow some signal interference to continue to corrupt the signal. The utilization 
of digital signal storage allows thorough post-processing to further enhance ECG signal quality 
(Pan and Tompkins, 1985). The improved signal quality allows metrics – such as heart rate – to 
be accurately measured. 
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Although electrical component design and algorithm implementation can improve signal 
quality and facilitate the analysis of physiological signals, the electrode sensor itself is an 
important component of the ECG measurement that significantly impacts signal quality when 
there is insufficient adhesion to the skin (Nemati et al, 2012). The Ag/AgCl electrode, the 
standard of noninvasive ECG measurement, utilizes a hydrogel medium to translate ionic charge 
movement through tissue into electrical current. However, these electrodes are used for no longer 
than 48 hours at a time during Holter monitoring due to the causation of skin irritation and the 
reduction of signal quality due to the drying of the hydrogel. 
To improve long-term sensor performance, FLEXcon USA © has produced an electrode 
that does not require quickly-drying gels to measure the ECG from the skin surface. This 
electrode design uses a patented Pressure Sensitive Adhesive (PSA) to promote high surface area 
skin-to-electrode adhesion. These electrodes require electrophoretic activation prior to clinical 
use, due to biocompatibility regulations established by the Association for the Advancement of 
Medical Instrumentation (AAMI), to limit sensor impedance. Last year’s Major Qualifying 
Project (MQP) designed a method by which to evaluate the compliance of the FLEXcon 
electrode with AAMI standards and the electrical short-term performance versus that of the 
standard Ag/AgCl electrode. 
This year, the current MQP group designed and conducted a method of clinically 
comparing long-term FLEXcon and Ag/AgCl electrode performances. This procedure addressed 
the numerous obstacles of physical and electrical interactions between the electrode and the skin, 
such as skin-to-electrode adhesion, repositionability, skin irritation, and ECG signal quality. The 
collaboration with FLEXcon to develop a biocompatible, strongly adhesive, and signal receptive 
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ECG electrode design will provide a means of ensuring high-quality, long-term, and in-home 
vital sign monitoring of arrhythmia-susceptible patients. 
7.2 Project Organization and Design 
 A series of clinical studies – encompassing an array of implemented measurement 
systems – was designed to provide a comprehensive functional analysis of FLEXcon adhesive 
performance in clinical settings versus that of the standard Ag/AgCl hydrogel. This overall 
objective was divided into a series of three stages or phases, as shown in the project design Gantt 
chart (Figure 7) and work breakdown structure (Figure 8). After discussing the needs of the 
client (FLEXcon), the group refined its project design to compare the physical limitations of the 
client’s four adhesive samples and determine which sample can exhibit a biocompatibility 
comparable to that of the Ag/AgCl electrode. After selecting a biocompatible electrode design, 
the MQP group developed a protocol to simulate long-term clinical vital sign monitoring. Then, 
a peak detection algorithm was designed to quantify ECG trace quality and compare the long-
term signal acquisition capabilities of the FLEXcon and hydrogel electrodes.  
7.3 Methods: Phase I 
 First, the client needed a means by which to determine the biocompatibility and physical 
limitations of four novel adhesive types. This clinical study was designed to recruit an ethnically 
diverse population of 10 human subjects, to reflect the diversity of the human population. Then, 
an experiment was conducted to correlate adhesion strength loss during repositioning to adhesive 
and body material type. CES EduPack, a material properties database, was utilized to select a list 
of materials that could be feasibly attached to a FLEXcon adhesive or hydrogel. Two of these 
materials – a rigid polypropylene foam and a flexible fabric material – were selected as 
substrates to be attached to a hydrogel and a FLEXcon adhesive. After sanitizing each subject’s 
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skin, an each preliminary electrode design was applied to each subject’s forearm. A manual 
tensile force transducer (National Instruments) was utilized to apply peeling and pulling forces 
via a metal wire connection and measure the maximum force required to remove each electrode 
from each subject’s forearm before and after electrode repositioning.  
 Next, a second experiment was designed to quantify the irritation induced by wearing the 
standard and FLEXcon adhesives. In this procedure, 4 FLEXcon adhesives and one hydrogel 
adhesive were attached to rigid foam bodies. Then, 7 of each electrode design were applied to 
each of the 10 subjects’ forearms after sanitizing the skin with ethyl alcohol prep pads. These 
subjects were instructed to not exercise during this 7-day clinical study. Then, every 24 hours, 
the subjects returned to the laboratory and completed a questionnaire to describe any experienced 
itchiness. The number electrodes that had fallen off of the subject in the past 24 hours was noted 
at the beginning of every session. Next, an electrode of each adhesive type was removed from 
each subject’s forearm, and any changes in coloration were noted. If either the itchiness or skin 
coloration started to become abnormal, all of the electrodes containing the irritating adhesive 
were removed.  
 The results of this biophysical study showed that a combination of carbon nanotubes, 
small concentrations of ionic salt, and a thick adhesive caused little to no skin irritation during 
the 7-day experiment. This superior FLEXcon adhesive was subsequently tested for long-term 
signal quality. 
7.4 Methods: Phase II 
 FLEXcon supplied electrodes consisting of either a novel adhesive or hydrogel signal 
receptive medium (SRM) attached to a polypropylene body material. Then, two experiments 
were conducted to create two correlations between adhesive type and ECG signal quality.  
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 The first experiment utilized the short-term ECG to measure signal quality as a function 
of electrode storage temperature. Both the FLEXcon and hydrogel electrodes were stored at -
80F, 160F, and room temperature for 72 hours (3 days) prior to use. Then, an ethnically diverse 
population of 10 subjects was recruited. Each subject was asked to sit in a seat and relax prior to 
the initiation of the study procedure. Then, each subject’s lower left abdomen in upper chest 
were cleansed with ethyl alcohol to remove any dead skin. After allowing the ethanol to 
evaporate, a FLEXcon electrode and a hydrogel electrode that were stored at room temperature 
were placed on the upper left and upper right chest, as well as on the lower left abdomen. These 
sets of electrodes were connected to a BIOPAC system that was used to measure each subject’s 
resting ECG for 3 minutes. Then, the electrodes were removed, the skin was cleansed, and the 3 
lead ECG was measured again using the electrodes stored at 160F and -80F. All ECG data was 
stored in a computer post-processing. 
 After the conclusion of this experiment, the subjects participated in a second clinical 
long-term experiment. This procedure was designed to use FLEXcon and hydrogel electrodes to 
measure the 5-lead ECG simultaneously over the course of 5 days (96 hours) to simulate long-
term vital sign monitoring.  
 First, each subject’s skin was cleansed with ethyl alcohol prep pads. After waiting 60 
seconds for the ethanol to evaporate, palpation was used to place a hydrogel and a FLEXcon 
electrode on each of 5 locations of the subject’s thorax: the lower right and left abdomen, the 
upper left and right chest, and the manubrium sterni. Then, a Holter monitor was connected to 
each set of electrodes via shielded leads. Each subject was subsequently attached to relax and sit 
in a chair for 5 minutes. Then, the subject was allowed to walk around the facility for 5 minutes. 
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The Holter monitors were powered off after data collection, and the measured data was stored in 
a computer for post-processing.  
 Next, an algorithm was designed to detect QRS complexes and measure heart rate in each 
stored ECG trace (Pan and Tompkins, 1985). The program utilized a series of digital filters to 
locate the time indices of the ECG signal R waves. First, the ECG signal was processed with a 
band-pass filter that removed extraneous environmental noise. Then, a derivative filter was 
implemented to accentuate the sharp voltage transitions that take place in the QRS complex due 
to rapid ventricular polarization and depolarization. The output of this filter was subsequently 
squared to reduce the amplitude of residual high frequency and low-amplitude noise. Finally, a 
hamming window average filter was used to generate a signal with maxima at the R wave peaks.  
 Next, a threshold was applied to the output of the moving average filter to generate a 
square wave. The waveform has a value of 1 at time indices when the moving average waveform 
is above threshold and has a value of zero when the moving average output is below threshold. 
Then, a new waveform was generated to detect one-to-zero and zero-to-one transitions in the 
square wave. From this derivative waveform, the boundaries of peak-searching domains were 
established. A series of logical circuits were used to find the times (in seconds) at which the 
moving average waveform has maxima within the peak-searching bounds.  
 After the storage of these peak location times in a single array, the heart rate of the 
waveform was calculated. First, the derivative of this time index array was calculated, producing 
an array of R-R intervals (in seconds per beat). The instantaneous heart rate was calculated with 
the following relation. 
Equation 8                                        :  ( )  
  
            ( )
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Lastly, the average of these instantaneous heart rate measurements was calculated to determine 
the average heart rate.  
 This algorithm performed these operations on both the FLEXcon and hydrogel ECG 
waveforms. The heart rate metric was utilized to quantify the functional differences between the 
two electrode designs. 
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Chapter 8: Conclusions and Recommendations 
8.1 Conclusions 
The two designed clinical studies effectively characterized electrode performance and 
helped the client improve its adhesive design. The first study focused on the measurement of 
mechanical stability and adhesive-to-skin interaction during use in a long-term vital sign 
monitoring environment. After establishing physical limitations of the client’s and industry 
standard adhesives, the second study was conducted to quantify ECG signal quality during both 
electrodes’ effective periods.  
The first clinical study established a preliminary biocompatibility benchmark that was 
utilized to select the least irritating and most mechanically stable adhesive of the client’s four 
presented formulas. The results of this study demonstrated that the Generation 2-A adhesive 
caused little to no irritation (with minor itching) and experienced minimal electrode-to-skin 
adhesion loss during a 7-day period. A short-term tensile force measurement protocol showed 
that polypropylene foam sufficiently provided the rigidity necessary to maintain electrode form 
in response to lead force retention.  
The second clinical study compared the ECG measurement capabilities of FLEXcon and 
hydrogel SRMs. An experiment was performed to determine the effect of temperature storage 
(72 hours) on ECG signal quality; reduction of P, Q, R, S, and T wave definition indicated loss 
of signal quality. The results demonstrated that temperatures between -80F and 160F did not 
cause significant differences in signal quality between the two tested adhesives. Then, a 4-day 
(96-hour) dynamic ECG measurement was conducted to observe changes in ECG signal 
definition in response to time and motion. The results of this experiment showed that while the 
subjects were at rest, both the FLEXcon and hydrogel electrodes maintained QRS complex 
Long Term Clinical Evaluation of Novel ECG Electrodes   
 112 
definition comparable to that of the standard hydrogel electrode throughout the 96-hour testing 
period. Utilization of the DFT to visualize motion artifacts during this 96-hour period showed 
that the FLEXcon electrode allowed frictional motion artifacts to reduce P and T wave 
definition. In comparison, the standard hydrogel dampened these motion artifacts more 
effectively during the first 48 hours; however, after 72 hours of use, the lack of moisture in the 
hydrogel sponge caused a more significant reduction of P and T wave definition and higher 
susceptibility to 60 Hz power line interference. 
Although both electrode types showed R wave amplitudes significantly above noise level, 
occasional high-amplitude, high-frequency motion artifacts caused the utilized peak detection 
algorithm to incorrectly identify R waves and incorrectly measure instantaneous heart rate. The 
use of a regression line to correlate the heart rates measured by FLEXcon and hydrogel 
electrodes during both resting and ambulatory positions showed that the correlation coefficients 
were equivalent (0.997). Both correlation coefficients were greater than 0.95 (p < 0.05), 
demonstrating statistically similar performance results between the two electrode adhesive types. 
8.2 Recommendations 
 The primary metrics of electrode performance during the second clinical study 
were average heart rate, heart rate variances, and rates of heart rate changes. All of these 
measurements were calculated based on the detection of R-R intervals via R wave detection, 
illustrating how well the tested electrodes facilitate basic clinical heart rate measurement. Thus, 
the prominence of the R-wave above noise determined whether the algorithm could measure the 
subject’s heart rate. In future work, peak detection based on other waves in the ECG can show 
how well the FLEXcon and hydrogel electrodes exhibit waves and complexes other than those 
found in the QRS complex. The ability of FLEXcon electrodes to accurately and precisely 
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measure subtle cardiac anomalies that may not impact the R wave during long-term vital sign 
monitoring could provide important information to clinicians and ultimately save more lives. 
At the conclusion of this long-term experiment, the electrodes were removed from the 
subjects’ skin. Redness and accumulation of oils were observed on the entire areas of contact 
between the hydrogel electrodes and the skin; only redness was observed on areas of contact 
between the FLEXcon electrode’s central signal-unifying bridge and the skin. This discoloration 
demonstrated that the bridge was inducing frictional shear on the skin and therefore introducing 
motion artifacts into the measured ECG. Thickening of the FLEXcon adhesive barrier would 
reduce friction (reducing the P and T wave distortions) as well as reduce sensations of skin 
discomfort and irritation. 
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Appendix 
%%Peak Detection Algorithm 
clc; clear all; close all; 
%% Read data 
data = load ('S7_R1.txt'); % Load data collected with Biopac system 
fc = data(:,2); %FLEXcon electrode data in second column, in Volts 
ag = data(:,1); %Ag/AgCl electrode data in first column, in Volts 
% data1 = load ('3-fc-d3-e.csv'); % Load data collected with Holter monitors 
% fc = data1(:,3); %FLEXcon electrode data uses channel 3, in Volts 
% data2 = load ('3-ag-d2-e.csv'); % Load data collected with Holter monitors 
% ag = data2(:,3); %Ag/AgCl electrode data uses channel 3, in Volts 
% fc= fc(1:24000); %Specified range of data for FLEXcon 
% ag= ag(1:24000); %Specified range of data for Ag/AgCl 
% All FLEXcon variables began with fc and Ag/AgCl variables with ag % 
%% The Number of Samples per 1 second and  
                 %the duration of the signal with time vector 
%Fs=200;  % Biopac system sampling frequency 
Fs=180;   % Holter monitor sampling frequency 
dt=1/Fs;  % time step between each sample 
duration=length(fc)*dt; % the duration of data in seconds (2 minutes) 
t=0:dt:duration-dt; % The vector of time 
t=t';   % it changes teh columns to rows 
%% Detrending solution 
%N=200; % 1 second long for detrending of Biopac system 
N=180;  % 1 second long for detrending of Holter monitors 
for i=1:N:length(fc)-N-1 
p1=polyfit(t(i:(i+N-1)),fc(i:(i+N-1)),1); % Coefficients for FLEXcon 
polynomial  
yfit1=polyval(p1,t(i:(i+N-1)));  
p2=polyfit(t(i:(i+N-1)),ag(i:(i+N-1)),1); % Coefficients for Ag/AgCl 
polynomial  
yfit2=polyval(p2,t(i:(i+N-1))); 
for j=1:N 
fc(i+j-1)=fc(i+j-1)-yfit1(j); % FLEXcon detrended of raw signal 
ag(i+j-1)=ag(i+j-1)-yfit2(j); % Ag/AgCl detrended of raw signal 
end 
end 
%% Remove the DC noise of the signal 
fc=fc-mean(fc); %FLEXcon signal  
ag=ag-mean(ag); %Ag/AgCl signal 
  
%% Plots the Raw data after removing DC noise. 
figure(1)  
plot(t,fc); % Plots FLEXcon signal 
grid on; hold on; 
plot(t,ag, 'r-.');  % Plots Ag/AgCl signal 
xlabel('Time [s]'); 
ylabel('Voltage [V]'); 
title('Raw ECG Waveform'); 
legend('FLEXcon','AgCl'); 
%% Low-pass filter 
bl=[1 0 0 0 0 0 -2 0 0 0 0 0 1]; % Coefficients b of the difference equation 
of low-pass filter 
al=[1 -2 1]; % Coefficients a of the difference equation of low-pass filter 
fc_lp=filter(bl,al,fc); %FLEXcon low-pass filter 
ag_lp=filter(bl,al,ag); %Ag/AgCl low-pass filter 
Long Term Clinical Evaluation of Novel ECG Electrodes   
 118 
%% High-pass filter  
bh=[-1 zeros(1,15) 32 zeros(1,15) 1]; % Coefficients b of the difference 
equation of high-pass filter 
ah=[1 1]; % Coefficients a of the difference equation of high-pass filter 
fc_hp=filter(bh,ah,fc_lp); %FLEXcon high-pass filter 
ag_hp=filter(bh,ah,ag_lp); %Ag/AgCl high-pass filter 
figure (2) 
plot(t,fc_hp); %FLEXcon signal after band-pass filter  
grid on; hold on; 
plot(t,ag_hp, 'r-.'); %Ag/AgCl signal after band-pass filter  
xlabel('Time [s]'); 
ylabel('Voltage [V]'); 
title(' Bandpass Filter of ECG Waveform'); 
legend('FLEXcon','AgCl'); 
  
%% Derivative filtering, squaring 
bd=(1/8)*[2 1 0 -1 -2]; % Coefficients b of the difference equation of 
derivative function 
ad=[1]; % Coefficients a of the difference equation of derivative function 
fc_der=filter(bd,ad, fc_hp); %FLEXcon derivative filter 
ag_der=filter(bd,ad, ag_hp); %Ag/AgCl Derivative filter 
fc_sq=(fc_der).^2; %FLEXcon, signal squared of derivation 
ag_sq=(ag_der).^2; %Ag/AgCl, signal squared of derivation 
  
%% Moving average filter 
N=30;  
bm=(1/N)*[ones(1,N)]; 
am=[1]; 
fc_m=filter(bm,am,fc_sq); %FLEXcon Moving Average filter 
ag_m=filter(bm,am,ag_sq); %Ag/AgCl Moving Average filter 
figure(3) 
plot(t,fc_m);  
xlabel('Time (s)');ylabel('Voltage (V)'); 
title('FLEXcon ECG Waveform for Moving Average Filtering'); 
figure(4) 
plot(t,ag_m, 'r');  
xlabel('Time (s)');ylabel('Voltage (V)'); 
title('AgCl ECG Waveform for Moving Average Filtering'); 
%% Thresholds set by the mean of MA signal  
thr_fc= mean(fc_m); %Threshold for FLEXcon signal is set by the mean of MA 
thr_ag= mean(ag_m);%Threshold for Ag/AgCl signal is set by the mean of MA 
fc_p=zeros(size(fc_m));%Sets all values below threshold to zero for FLEXcon 
ag_p=zeros(size(ag_m));%Sets all values below threshold to zero for Ag/AgCl  
fc_p(find(fc_m>=thr_fc))=1; %All values above threshold are 1 for FLEXcon 
ag_p(find(ag_m>=thr_ag))=1; %All values above threshold are 1 for Ag/AgCl 
figure(5) 
plot(t,fc_p) 
hold on; grid on; 
plot(t,ag_p, 'r-.'); 
xlabel('Time [s]'); 
ylabel('Amplitude [filt V]'); 
title('Square ECG Peak Waveform'); 
legend('FLEXcon','AgCl'); 
%% searches for peaks between rising edges and falling edges 
a1=diff(fc_p); %Derivative of square signal, FLEXcon 
a2=diff(ag_p); %Derivative of square signal, Ag/AgCl 
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upindex_fc=find(a1==1); %Rising edges for FLEXcon 
upindex_ag=find(a2==1); %Rising edges for Ag/AgCl 
downindex1=find(a1==-1);%Falling edges for FLEXcon 
downindex2=find(a2==-1); %Falling edges for Ag/AgCl 
%% FLEXcon, peak detection  
prev_peak_fc=0; 
for i=1:min(length(upindex_fc),length(downindex1)) 
[amp1,indtemp1]=max(fc_hp(upindex_fc(i):downindex1(i))); 
indmax1(i)=indtemp1+upindex_fc(i)-1; 
rpeak_fc(i)=t(indmax1(i)); 
bpm_fc(i)=60./(rpeak_fc(i)-prev_peak_fc); 
prev_peak_fc=rpeak_fc(i); 
end 
%% Ag/AgCl, peak detection 
prev_peak_ag=0; 
for i=1:min(length(upindex_ag),length(downindex2)) 
[amp2,indtemp2]=max(ag_hp(upindex_ag(i):downindex2(i))); 
indmax2(i)=indtemp2+upindex_ag(i)-1; 
rpeak_ag(i)=t(indmax2(i)); 
bpm_ag(i)=60./(rpeak_ag(i)-prev_peak_ag); 
prev_peak_ag=rpeak_ag(i); 
end 
  
%% PD plots 
figure(6)  
plot(t, fc_hp) 
hold on; grid on; 
plot(rpeak_fc, fc_hp(indmax1),'or'); 
xlabel('Time (s)');ylabel('Voltage after BP filtering (V)'); 
title('FLEXcon ECG Waveform') 
figure(7)  
plot(t, ag_hp,'k') 
hold on; grid on; 
plot(rpeak_ag, ag_hp(indmax2),'xr'); 
xlabel('Time (s)');ylabel('Voltage after BP filtering (V)'); 
title('Ag/AgCl ECG Waveform') 
%% Cubic interpolation of R-R interval  
RR_fc=diff(rpeak_fc); %Difference in time between R-R intervals, FLEXcon 
RR_ag=diff(rpeak_ag); %Difference in time between R-R intervals, Ag/AgCl 
time_lr_fc=zeros(1,length(RR_fc)); 
time_lr_ag=zeros(1,length(RR_ag)); 
time_lr_fc(1)=0; 
for i=2:length(RR_fc) 
time_lr_fc(i)=sum(RR_fc(1:i-1)); 
end 
time_lr_ag(1)=0; 
for i=2:length(RR_ag) 
time_lr_ag(i)=sum(RR_ag(1:i-1)); 
end 
timeRR_fc=0:1/4:sum(RR_fc)-1/4; 
timeRR_ag=0:1/4:sum(RR_ag)-1/4; 
ys_fc=interp1(time_lr_fc,bpm_fc(1:length(time_lr_fc)),timeRR_fc,'spline'); 
ys_ag=interp1(time_lr_ag,bpm_ag(1:length(time_lr_ag)),timeRR_ag,'spline'); 
figure(8) 
plot(timeRR_fc,ys_fc, 'b+-') 
grid on; hold on; 
plot(timeRR_ag,ys_ag,'r.-') 
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xlabel('Time [s]'); 
ylabel('Beats per Minute'); 
title('Cubic Interpolation of HR Time Intervals'); 
legend('FLEXcon cubic interpolation','AgCl cubic interpolation'); 
ys_fc= ys_fc-mean(ys_fc); 
ys_ag= ys_ag-mean(ys_ag); 
  
%% Power Spectral Density (PSD) 
[psd_cubic_fc,f]=pwelch(ys_fc,length(ys_fc),[],512,4); 
[psd_cubic_ag,f]=pwelch(ys_ag,length(ys_ag),[],512,4);  
psd_cubic_fc=(abs(psd_cubic_fc)).^2; 
psd_cubic_ag=(abs(psd_cubic_ag)).^2; 
figure(9)  
plot(f,psd_cubic_fc, 'LineWidth',3) 
xlim([0 0.5]) 
grid on; hold on; 
plot(f,psd_cubic_ag, 'r-.','LineWidth',3) 
xlabel('Frequency in Hz'); 
ylabel('Power'); 
title('Representative Power Spectral Density Comparison'); 
legend('FLEXcon Electrodes','Ag/AgCl Electrodes') 
%% LF/HF 
low_index=find(f>=0.04 & f<=0.15); 
low_f=f(low_index); 
low_psd_cubic_fc=psd_cubic_fc(low_index); 
low_psd_cubic_ag=psd_cubic_ag(low_index); 
high_index= find(f>=0.15 & f<=0.4); 
high_f=f(high_index); 
high_psd_cubic_fc=psd_cubic_fc(high_index); 
high_psd_cubic_ag=psd_cubic_ag(high_index); 
NmuPeak_fc=length(rpeak_fc) 
NmuPeak_ag=length(rpeak_ag) 
LF_fc= sum(low_psd_cubic_fc) 
LF_ag= sum(low_psd_cubic_ag) 
HF_fc= sum(high_psd_cubic_fc) 
HF_ag= sum(high_psd_cubic_ag) 
LFHF_fc= LF_fc/HF_fc 
LFHF_ag= LF_ag/HF_ag 
%% Mean, Standard Deviation, RMSSD, SDNN 
Energy_fc=sum((fc_hp).^2) 
Energy_ag=sum((ag_hp).^2) 
Power_fc =Energy_fc./(length(fc_hp)) 
Power_ag =Energy_ag./(length(ag_hp))  
mean_bpm_fc= mean(bpm_fc) 
mean_bpm_ag= mean(bpm_ag) 
std_bpm_fc= std(bpm_fc) 
std_bpm_ag= std(bpm_ag) 
sumSD_fc=0; 
sumSD_ag=0; 
for i=2:1:length(RR_fc) 
sumSD_fc= sumSD_fc+ ((RR_fc(i)-RR_fc(i-1))^2); 
end 
for i=2:1:length(RR_ag) 
sumSD_ag= sumSD_ag+ ((RR_ag(i)-RR_ag(i-1))^2); 
end 
RMSSD_fc= sqrt(sumSD_fc./(length(RR_fc)-1)) 
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RMSSD_ag= sqrt(sumSD_ag./(length(RR_ag)-1)) 
SDNN_fc= std(RR_fc) 
SDNN_ag= std(RR_ag) 
temp1=[LF_fc HF_fc; 
    LF_ag HF_ag] 
temp2=[LFHF_fc mean_bpm_fc std_bpm_fc RMSSD_fc SDNN_fc; 
LFHF_ag mean_bpm_ag std_bpm_ag RMSSD_ag SDNN_ag] 
 
